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ABSTRACT

THE ZUCKER RAT AS A MODEL OF OBESITY-HYPERTENSION
by Ryan Morrison
Hypertension is a serious health problem that affects approximately 1 in 4 American
adults. Most cases are diagnosed as essential hypertension, meaning that the exact cause
is unknown. In most patients, however, excess weight is a major contributory factor to
the development of essential hypertension. The role of obesity in promoting
hypertension is now well documented and has become the foundation for an entire field
of research known alternately as obesity-hypertension, obesity-induced hypertension, or
obesity-associated hypertension. In this field, rapid advances are being made in our
understanding of how obesity and hypertension are linked. A plethora of related risk
factors, mediators, and pathways have now been identified and described through the use
of a variety of animal models. Nonetheless, the relationships between these factors and
the extents to which they promote obesity-hypertension are often poorly understood.
Unscrambling the various cardiovascular and metabolic determinants of obesityhypertension remains a persistent problem because both obesity and hypertension
typically exhibit polygenic etiologies and diet-dependent dynamics in humans. The
judicious use of appropriate animal models promises to be an important tool in this quest.
In addition, animal models are vital platforms for designing and evaluating approaches to
the treatment of obesity-hypertension. One model of particular interest is the obese
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Zucker rat, which develops extreme obesity but only develops slight, if any,
hypertension. The primary objective of the research in this dissertation was to determine
whether obese rats were more sensitive to experimental conditions known to induce
hypertension than age- and gender-matched lean controls. Lean and obese Zucker rats
were subjected to two experimental protocols that are known to induce hypertension in
other rodent strains: (1) the administration of deoxycorticosterone-acetate and salt to
uninephrectomized rats and (2) feeding rats a moderately high fat, salt-supplemented
(MHF-SS) diet. In each case, the obese Zucker rat was found to be more susceptible to
the development of hypertension. A second goal of this research was to ascertain a
possible mechanism through which the MHF-SS diet might induce hypertension in obese
Zucker rats. In this regard, dysfunction of the nitric oxide system, particularly in the
kidney, was implicated in the pathogenesis of the MHF-SS diet in obese Zucker rats. In
conclusion, this research suggests that the obese Zucker rat is labile with regard to blood
pressure and that renal nitric oxide dysfunction may promote hypertension when obese
Zucker rats are fed a moderately high fat, high salt diet.
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PREFACE
The primary research in this dissertation is composed of two published, peerreviewed manuscripts (chapters 2 and 3) and a manuscript that will be submitted for
publication (chapter 4). These manuscripts are summarized and expanded on in the
conclusions (chapter 5). In addition, sections of the literature review (chapter 1) may
eventually be revised and submitted for publication. The literature review establishes the
importance of animal models to the study of obesity-hypertension and briefly highlights
the advances being made with popular models. Chapters 2 and 3 describe the
development of the deoxycorticosterone acetate-salt treated obese Zucker rat model,
while chapter 4 discusses a model using a moderately high fat, salt-supplemented diet in
the obese Zucker rat.
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CHAPTER I
Literature Review

Introduction
Obesity is now recognized by the World Health Organization as a critical global health
problem (WHO, 2000). Recently, the prevalence of obesity has skyrocketed in the
United States and other industrialized countries. According to the National Health and
Nutrition Examination Studies (NHANES), obesity levels in the United States grew from
about 14% to nearly 31% from 1980 to 2000 (Flegal et al., 2002). Despite increased
awareness, the prevalence of obesity has continued to rise and we now face a worldwide
epidemic of obesity-related health problems. To make matters worse, children are being
increasingly affected (Sorof et al., 2004) and clinical interventions that promote
population-wide weight control have been generally ineffective. Consequently, pressure
to develop our understanding of obesity and how it contributes to other disease states is
quickly mounting.

Because the prevalence of obesity has risen so rapidly, it seems clear that environmental
factors are ushering in this change. In particular, the widespread adoption of high fat
diets (Lissner and Heitmann, 1995) and sedentary lifestyles have been implicated
1

(Williamson et al., 1993). This precipitating effect of lifestyle changes on the increasing
incidence of obesity, however, does not rule out the potential of a strong genetic
component in the development of obesity. To the contrary, an environment of nutrient
excess may allow for the full expression of obesity promoting genes that were previously
masked when nutrients were less abundant. It is likely that genes that participate in
determining energy balance, metabolism, and some behavioral traits are cooperating with
environmental changes to ultimately regulate, or fail to regulate, weight gain. In much
the same way that an individual’s complex genetic background determines susceptibility
to obesity, genetic background determines the susceptibility of obese individuals to a
number of obesity-associated comorbidities as well.

Obesity has been defined in various ways. Clinicians in the United States have
historically used height-weight based mortality data from the Metropolitan Life Insurance
Company to define obesity. Currently, the body mass index (BMI) is the most widely
accepted standard (Kushner, 1993). BMI is defined as weight in kg divided by height in
meters, squared. Since cardiovascular risks begin to increase substantially when BMI
increases above 25, a BMI greater than 25 is typically used to define clinically
overweight individuals. Nearly two thirds of the US population (64%) is overweight by
this definition (Flegal et al., 2002). Admittedly, this method often inappropriately
classifies muscular individuals as clinically overweight. Consequently, methods that
assess adipose tissue mass and distribution more accurately than BMI may constitute the
future standard. Regardless of how obesity is defined, there is abundant evidence to
indicate that excessive body weight is associated with elevated mortality rates. The
2

magnitude of this obesity-associated risk is further influenced by age, gender, and the
pattern of fat distribution (Kushner, 1993). For example, abdominal obesity appears to
disproportionately increase the risk of developing certain comorbidities such as
cardiovascular disease (Sundquist et al., 2001).

Paralleling the rise in obesity, the prevalence of hypertension has also increased in the
last decade. Roughly 29% of the US population over the age of 18 and 65% of the US
population over the age of 60 is hypertensive based on the criteria of a blood pressure in
excess of 140/90 mmHg or use of hypertensive medications (Hajjar and Kotchen, 2003).
The rise in the prevalence of obesity is a chief factor in the increased incidence of
hypertension (Care, 2005), which can lead to stroke, heart failure, kidney failure, and
other serious health complications.

Obesity and hypertension are common in developed countries, but the rate of cooccurrence of these two disorders in a single individual cannot be explained by mere
random coincidence (Hsueh and Buchanan, 1994). Hypertension occurs in 25% to 50%
of obese individuals, which is a significantly higher prevalence than in the general
population (Bell, 1990). According to risk estimates from the Framingham Heart Study,
obesity is linked to about 75% of male and about 65% of female cases of hypertension
(Davy and Hall, 2004; Garrison et al., 1987). Even in patients who are not obese, modest
changes in body weight have been positively correlated with blood pressure, although
individuals vary in their susceptibility to this effect (Davy and Hall, 2004).
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Genetic factors such as ethnicity can determine whether obesity will lead to hypertension.
Pima Indians have a high rate of obesity, but a low rate of hypertension (Weyer et al.,
2000). In addition, hypertension is more prevalent in black men than white men, despite
comparable levels of obesity (Abate et al., 2001). Similarly, genetically obese animals
vary in their predisposition to hypertension depending on the specific strain being
studied. The variation may depend on the specific mechanisms underlying the
development of obesity (Mark et al., 1999) or on blood pressure control mechanisms.

Although the connection between obesity and hypertension was recognized nearly a
century ago (Antic et al., 2003), we are still at a relatively early stage in achieving the
goal of fully understanding the complex neural, cardiovascular, and hormonal pathways
that lead from obesity to hypertension. The pace of advance is accelerating, however, in
the wake of a growing multitude of manipulations and mutations available in animals for
modeling and investigating human obesity-associated hypertension. Even now, existing
animal models have provided a foundation of knowledge and hold the potential to
unscramble many of the cardiovascular and metabolic determinants of obesityhypertension. Additionally, novel animal models are rapidly emerging as valuable tools
in the quest to discover and evaluate the genetic mutations and pathophysiological
pathways that contribute to complex cardiovascular disorders such as obesityhypertension.

In humans, both obesity per se and hypertension per se are typically caused by complex
interactions of multiple environmental and genetic factors, resulting in a multiplicity of
4

etiologies for each disease. Thus, neither obesity-hypertension nor its components
(obesity and essential hypertension) can be completely explained by a single
pathophysiological mechanism. More likely, a plethora of convoluted pathways with
varying levels of significance will need to be elucidated in order to fully comprehend the
role of obesity in promoting hypertension.

It has been previously reported that the establishment of cause-and-effect relations in the
field of obesity-hypertension is hindered by a shortage of suitable animal models, which,
if available, would allow monitoring of the sequence of renal, cardiovascular, and
endocrinological functional changes during the development of obesity (Hall et al.,
1993). Meaningful advances in the field of obesity-hypertension depend upon the
development of an assortment of animal models that have characteristics in common with
those observed in obesity-hypertension in humans. These advances may be facilitated by
sophisticated techniques that are designed to evaluate complex networks of gene
interactions, such as the integrated genomics approach that was proposed by Schadt et al.
(2005). Alternative statistical models such as factor analysis or structural equation
modeling might also be required to unravel the complex network of pathways than link
obesity to hypertension (Chan et al., 2002). Meta-analyses, which are performed by
synthesizing research results from previously separate, yet related, studies, can now
compile past and current research from diverse model-specific studies. As our
knowledge of the mechanistic basis of obesity-hypertension advances, new potential
targets for treatment may emerge.

5

Some of the factors that have been implicated in obesity-hypertension are represented in
the disorder known alternately as the insulin resistance syndrome, the metabolic
(cardiovascular) syndrome (X), and/or the “deadly quartet.” Although this syndrome has
been defined in various ways, obesity and hypertension are central and persistent
elements. Junquero et al. (2005) recently summarized the varying syndrome definitions
as “the clustering of moderate troubles of glucose, lipid metabolism, body weight,
hypertension and vascular inflammation.” The most commonly used clinical definition
seems to be The National Cholesterol Education Program’s Adult Treatment Panel III
report (ATP III), which lists the characteristics of the metabolic syndrome as abdominal
obesity , atherogenic dyslipidemia, elevated blood pressure, insulin resistance, a
proinflammatory state, and a prothrombotic state. This clustering is well documented in
humans (Aizawa et al., 2005) and is present in many of the animal models of obesityhypertension, illustrating both the multifactorial nature of obesity-hypertension and the
highly conserved nature of these dysfunctional metabolic relationships in mammals.
While obesity may play the most pivotal role in promoting hypertension, it is believed
that each of the aforementioned clustering elements can play a role in the advancement of
blood pressure dysregulation (Morse et al., 2005). Thus, models that overexpress or lack
these clustering elements may be invaluable for discerning how their association with
obesity may play a role in promoting hypertension.

6

Models of Obesity-hypertension: An Overview
An ideal animal model for a disease “closely represents most or all of its
pathophysiological characteristics (Tschop and Heiman, 2001).” Although a number of
factors have been implicated, the pathophysiological characteristics of obesityhypertension have not been clearly defined yet. Moreover, no single animal model is
universally representative of obesity-hypertension, although some models exhibit many
of the aforementioned clustering factors. Hence, nearly any animal that expresses obesity
and hypertension may serve as a viable research tool, even if obesity and hypertension
are not coupled. At this juncture, it appears that the most practical approach to the study
of obesity-hypertension would be to use a wide range of species/models.

Fortunately, experimental obesity has now been produced in a large assortment of rodents
using dietary manipulation, chemical and surgical treatments, selective breeding, and/or
genetic manipulation (Tschop and Heiman, 2001). Many, but not all, of these models
spontaneously develop hypertension as they age and gain weight. Such models are
naturally suited for the study of obesity-hypertension. In addition, many of the remaining
models of obesity may still be developed into models of obesity-hypertension by
applying additional hypertensive influences. For example, results from our laboratory
and others indicate that obese rodents may be more vulnerable to the hypertensive
influence of salt than their lean counterparts (Dobrian et al., 2003; Morrison et al., 2002;
Radin et al., 2003). This association between obesity and salt-sensitivity of blood
pressure is also evident in humans and other animals, although the exact mechanism
linking these conditions is not fully understood (Rocchini, 2000).
7

Besides salt, several other environmental stimuli may be useful as tools for developing
models of obesity-hypertension. For example, high protein intake has been positively
associated with changes in blood pressure in humans (Suter et al., 2002). Alternatively,
reducing the metabolic rate by elevating ambient temperatures or increasing caloric
intake with palatable diets can directly promote obesity (Tschop and Heiman, 2001),
thereby indirectly promoting hypertension. Diets that are high in fat and refined
carbohydrates have been shown to promote both obesity and hypertension in inbred rats
(Barnard et al., 1993). Moreover, saturated fats and refined carbohydrates have been
associated with salt retention and hypertension in humans (Preuss, 1997). Fortunately,
researchers now benefit from the increasing commercial availability of standardized and
purified diets with adaptable macronutrient compositions.

Numerous factors determine the most appropriate model selection for an investigator:
research scope and objectives, institutional resources, cultural biases regarding species of
animals, and individual investigators’ preferences. In the US, rodents have been the
dominant species adopted for research (FBR, 2006; Jacoby, 1998). They feature low
breeding and maintenance costs (Fitzgerald, 1983), easy handling and feeding, short
lifespans, wide commercial availability, minimal cultural backlash, and a well-understood
physiology. For that reason, this overview focuses primarily on rodents. However, it
should be noted that excellent models of obesity-hypertension have been developed using
dogs (Rocchini et al., 1987) and rabbits (Carroll et al., 1996) and may be developed from
other animals as well.
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When using an animal model, careful consideration has to be given to factors such as age
and gender when designing experiments and interpreting data. For example, it is known
that gender can have a significant effect on susceptibility to blood pressure elevation in
rodents; however, the exact nature of the effect varies across strains (Herrera and RuizOpazo, 2005). Susceptibility to hypertension is also influenced by age in rodents, which
generally have lifespans of about two years. A good time to initiate many studies may be
at about 100 days, when rats cease to gain lean mass, but when fat mass may still be
accrued (Tschop and Heiman, 2001) Aging in rats may result in increased susceptibility
to hypertension (Ren et al., 1999). This is consistent with human observations, where the
prevalence of hypertension and obesity have been shown to increase with age (Bray and
Gray, 1988; Kannel et al., 1967). This association between obesity and hypertension in
humans, however, tends to weakens with advanced age (Van Itallie, 1985).

Another important general consideration with respect to rodent models is the breeding
source and method. Inbred and outbred strains that conform to established standards of
breeding are widely available from reputable commercial vendors. Outbred strains have
greater genetic diversity, making them well suited as a model for pharmacological studies
that attempt to understand how a drug will behave in a diverse population. Inbred
animals have a high occurrence rate of potentially harmful and confounding homozygous
recessive mutations. Furthermore, inbred animals are subject to genetic homeostasis
(Hartl, 2000), a paradoxical effect which leads to a counter intuitive elevated variance
with respect to many of the measurable quantitative characteristics in inbred rodents
9

(Phelan and Austad, 1994). Despite this drawback, inbred animals still have distinct
advantages. They allow reliable comparison of data across laboratories because the
population is genomically stable and can be repeatedly accessed. The fixed genotypes of
inbred animals also allow investigators to isolate the influence of environment from
unknown genetic variations that may play a role in determining phenotype. Perhaps most
importantly, these models can be rapidly developed and are an invaluable tool for
functional genomics, as demonstrated by Svenson et al. (2003).

Model Categories
Rodents that develop obesity as a result of a single gene mutation can still be outbred to
maintain genetic diversity throughout the rest of their genetic background (e.g. the obese
Zucker rat). These outbred monogenic models of obesity provide an excellent source for
well-controlled, reproducible analysis of specific pathophysiologic links between obesity
and hypertension. In addition, they provide a unique opportunity to study the individual
contributions of specific metabolic dysfunctions in obesity-hypertension and are
invaluable for testing translational clinical advances that relate to rare monogenic forms
of obesity-hypertension.

Rodent models with hypertension resulting from polygenic obesity are in some ways the
most relevant for studying human obesity-hypertension. In particular, such models are
well-suited for the investigation of generalized therapeutic approaches to obesityhypertension. As demonstrated by Tsukahara et al. (2004), intercrossing strains with
specific “clustered” phenotypes that are associated with hypertension is also a useful tool
10

for understanding polygenic hypertension. Conversely, this study indicated that, in some
cases, the development of obesity and the development of hypertension are not
genetically associated in some inbred mouse models of obesity-hypertension.

In order to simplify discussion of the strengths and weaknesses of individual models, they
are classified in this section according to the following schema, which was loosely based
on the system used by Sun and Zhang to review animal models of hypertension per se
(Sun and Zhang, 2005). The models of obesity-hypertension are categorized as genetic,
dietary, or treatment models, depending on the methods used to produce the model and
the underlying basis of obesity-hypertension. These categories are given original
definitions so that all existing models of obesity-hypertension fall into a specific
category. Of course, it may be possible to develop a hybrid model that does not fit neatly
into any single category. In addition, models of obesity-hypertension based on
environmental factors such as temperature change or stress induction have not been
developed, so they are not given a category, although it may be possible to develop such
a model.

Genetic Models
Genetic models of obesity-hypertension spontaneously develop both obesity and
hypertension on standard laboratory diets as a result of their genetic makeup. Such
models can be produced with targeted mutagenesis, transgenics, or selective breeding of
spontaneous mutants. These are the most popular and widely used models, probably
because they generally require the least technical input, the role of confounding factors is
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minimized, and research can be focused on the mechanisms that explain how specific
mutations give rise to obesity and hypertension. Currently, the obesity component in
most of the genetic models is based on disorders of leptin signaling and transduction.
Prominent examples of genetic models with leptin dysfunction include the fa/fa rat, ZSF1
rat, SHROB rat, and ob/ob mouse.
The Spontaneously Hypertensive Obese Rat (SHROB)
The spontaneously hypertensive obese rat (SHROB; Koletsky) was developed by Richard
Koletsky at Case Western Reserve Medical center after he discovered a spontaneous
mutation, designated corpulent (cp), that results in a shortened and completely
nonfunctional leptin receptor. The cp mutation was crossed onto the spontaneously
hypertensive rat (SHR/N) background, resulting in the SHROB (Greenhouse, 1990). In
the SHROB, hypertension and obesity are caused by independent genetic mutations.
Studies showing that SHROBs are not any more hypertensive than SHR/Ns suggest that
genetically determined hypertension is not exacerbated by genetically determined obesity
in this model (Ernsberger et al., 1999b). Since the SHROBs also exhibit severe
hyperinsulinemia and insulin resistance, this blood pressure data also suggests insulin
resistance does not contribute to hypertension in this model (Friedman et al., 1997). The
decoupling of obesity and hypertension in the SHROB may preclude its use as a model
for identifying specific metabolic factors that link obesity to hypertension. Nevertheless,
the SHROB has proven to be quite useful as a tool for investigating pharmacological
approaches for the treatment of obesity-hypertension (Ernsberger et al., 1997; Ernsberger
et al., 1999a; Friedman et al., 1998; Koletsky et al., 2003; Mukaddam-Daher et al., 2003)
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and is considered by some to be a good model for metabolic syndrome X (Ernsberger et
al., 1999a; Velliquette and Ernsberger, 2003).
Obese Zucker Rat (OZR)
The obese Zucker rat (OZR) was discovered by Drs. Theodore and Lois Zucker after a
spontaneous mutation, designated fatty (fa), occurred in an outbred stock of their rats
(Greenhouse, 1990). The mutation, located in the gene for the leptin receptor (Takaya et
al., 1996), is autosomal recessively inherited. Severe obesity results because the rat,
which has a diminished ability to respond to leptin, becomes hyperphagic.

Conflicting data exists as to whether the obese Zucker rat is actually hypertensive. Some
investigators have reported that the OZR is not hypertensive relative to lean Zucker rats
(Bunag and Barringer, 1988; Morgan et al., 1995; Pamidimukkala and Jandhyala, 1996;
Pawloski et al., 1992; Reddy and Kotchen, 1992), whereas other investigators have
indicated that the OZR is hypertensive, although the degree of hypertension reported is
generally mild (Alonso-Galicia et al., 1996; Ambrozy et al., 1991; Carlson et al., 2000;
Kurtz et al., 1989; Maher et al., 1995; Turner et al., 1995). The OZR appears to be
slightly salt-sensitive (Carlson et al., 2000; Reddy and Kotchen, 1992) and experiments
in our laboratory have shown that this sensitivity can be exacerbated by DOCA and
uninephrectomy (Morrison et al., 2002) or a high fat diet (not submitted for publication
yet). The OZR also develops marked insulin resistance, hyperinsulinemia,
hypertriglyceridemia, and hypercholesterolemia. In addition, the renin-angiotensin
system may play a role in mediating hypertension in this model (Alonso-Galicia et al.,
1996).
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Wistar Fatty (WFR)
The fatty gene that spontaneously arose in obese Zucker rats was backcrossed onto
outbred Wistar rats by Dr. Hitoshi Ikeda at Takeda Chemical Industries in Osaka, Japan
(Greenhouse, 1990). The Wistar fatty rat (WFR) becomes spontaneously hypertensive,
hyperglycemic, and hyperinsulinemic in association with increased sympathetic nervous
system activity (Suzuki et al., 1999; Yamakawa et al., 1995). In addition, the WFR also
exhibits salt sensitivity of blood pressure (Hayashida et al., 2001) and a shifted pressure
natriuresis curve (Suzuki et al., 1996). Unfortunately, the American colony of WFRs at
Indiana University Medical Center was lost (Greenhouse, 1990) and it seems that
research on this strain is limited primarily to Japan.
11-β-Hydroxysteroid Dehydrogenase type 1 (11βHSD1) transgenic mice
In humans, 11-beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) converts inactive
cortisone to biologically active cortisol (Dotsch and Rascher, 2002). In rodents,
11βHSD1 converts inactive 11-dehydrocorticosterone to active corticosterone, the major
rodent glucocorticoid (Draper and Stewart, 2005). Thus, the main function of 11βHSD1
is to convert specific inactive glucocorticoid metabolites to glucocorticoid metabolites
that can activate the glucocorticoid receptor (Draper and Stewart, 2005). Glucocorticoids
play an important role in fat metabolism and in the distribution of adipose tissue.

11βHSD1 has been linked to obesity and insulin resistance in humans (Draper and
Stewart, 2005). Jeffrey Flier’s group in Boston recently developed a strain of transgenic
mice that overexpress 11βHSD1. These mice developed visceral obesity and exhibited
other symptoms of the metabolic syndrome (Masuzaki et al., 2001). They also developed
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salt-sensitive hypertension that may be mediated by the renin-angiotensin system
(Masuzaki et al., 2003).
New Zealand Obese Mice (NZO)
New Zealand obese (NZO) mice were developed by selectively breeding obese agouti
mice for 5 generations (Giesen et al., 2003). The NZO spontaneously develops obesity
and hypertension, as well as insulin resistance, hypertriglyceridemia, and
hypercholesterolemia (Ortlepp et al., 2000). Diabetes develops by six to twelve months
in the NZO due to a loss of pancreatic β-cells (Plum et al., 2002). Moreover, high fat
feeding accelerates or worsens many of the pathophysiological symptoms that are
exhibited by the NZO, suggesting that the NZO may be useful in assessing the role of
diet in the development of obesity-hypertension (Giesen et al., 2003; Plum et al., 2002).

Dietary Models
There are a number of commercially available diets that can produce obesity in certain
susceptible rodents. In turn, these obesity-prone rodents may develop hypertension over
a period of time. Dietary models develop obesity as a result of polygenic susceptibility to
obesity and hypertension upon exposure to dietary manipulation. Thus, genetics plays a
role in determining obesity and hypertension in these models, although this confounding
factor may be controlled somewhat by using inbred animals. Animals that gain excessive
weight on the special diets are considered to be genetically susceptible, whereas those
which are resistant to weight gain are considered to be genetically resistant (Levin et al.,
1987). Dietary models are perhaps the most relevant type of model because they closely
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resemble the etiology of human obesity-hypertension. In particular, high fat feeding
produces obesity that “closely mimics the metabolic, neurohumoral, renal, and
cardiovascular changes observed in obese humans” (Hall et al., 2003b). Dietary models
have the potential to become a powerful tool for elucidating the complex interplay
between genetics and environment that determines whether obesity produces
hypertension. In addition, these models can be used to discover previously unconsidered
obesity-hypertension genes and markers and to investigate dietary and therapeutic
approaches for the treatment of obesity-hypertension. Examples of dietary models of
obesity-hypertension include the purified moderately high fat diet used by Dobrian et al.
(2000) and the high-fat refined carbohydrate diets used by Barnard, Roberts and
associates (Barnard et al., 1993). These models have thus far tended to show the
importance of oxidative stress (Dobrian et al., 2001; Roberts et al., 2005) and nitric oxide
dysfunction (Dobrian et al., 2001; Roberts et al., 2003) as a factor in obesityhypertension.

Treatment Models
Treatment models use surgical manipulations or chemical injections to produce or
exacerbate obesity and/or hypertension. Of course, genetic background still plays an
important role in determining susceptibility, just as in dietary models. Hypertension can
be experimentally induced using a wide array of surgical and chemical methods,
including clipping the renal arteries, wrapping the kidneys, injecting salt retaining agents
into uninephrectomized rats (e.g DOCA), and by administering NOS inhibiting agents
such (e.g. L-NAME) (Sun and Zhang, 2005).
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Animal models of obesity have been developed using a variety of chemical and surgical
means. For example, obesity can be produced by radiofrequency, electrolytically, or
surgical lesions the paraventricular or the ventromedial nuclei of the hypothalamus.
Also, a number of chemical agents, including colchicine, kainic acid, ibotenic acid,
monosodium glutamate, piperidyl mustard, goldthioglucose, and monosodium glutamate
can be administered to produce obesity (Tschop and Heiman, 2001). These methods
have been used primarily to study obesity per se but it may be possible to apply these
techniques with different strains and diets to develop new models of obesityhypertension.
DOCA-salt treated obese Zucker rat (DST-OZR)
Our lab has recently used DOCA-salt treatment of obese Zucker rats (DST-OZR) to
determine whether obesity increases the sensitivity of rats to experimentally induced
hypertension. DST-OZRs become severely hypertensive within a few weeks of initiating
treatment, whereas genetically lean Zucker rats were far less affected (Morrison et al.,
2002). Furthermore, OZRs developed more extensive glomerulosclerotic kidney damage
than LZRs, with or without DOCA-salt treatment (Morrison et al., 2005). This is
consistent with reports that classify obesity as a risk factor for nephropathy, especially
focal segmental glomerulosclerosis (Cohen, 1999). Additionally, obesity is known to
aggravate renal dysfunction in humans (Sasatomi et al., 2001). With respect to this, we
have observed significant proteinuria in the DST-OZR, indicating that functional damage
to the kidney takes place in these animals (Morrison et al., 2005). It is currently unclear,
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however, whether these changes are caused by obesity itself or by the associated
hypertension and hyperlipidemia (Sasatomi et al., 2001).

The DST-OZR model is described in chapters 2 and 3. This model effectively illustrates
the susceptibility of obese rats to hypertensive pressures. It may also be well suited for
studying how obesity affects the rate of end organ damage in malignant hypertensive
states (Morrison et al., 2005).
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Monosodium Glutamate Injected Hypertensive Rats
Monosodium glutamate (MSG) has been used to create models of obesity-hypertension
from known models of hypertension per se, including the SHR (van den Buuse et al.,
1985) and the 1-kidney, 1-clip hypertensive (1K1C) rat (Correa and Saavedra, 1992).
MSG is injected into the bodies of neonatal rats, where it travels to the hypothalamus and
overexcites neurons to the point of cell death, causing an obesity producing lesion.
Despite the independence of obesity and hypertension in the MSG injected SHR, this
model still displays at least a weak relationship between obesity and hypertension. For
example, blood pressure is lower in MSG-treated SHR than in control SHR (van den
Buuse et al., 1985), whereas it may not be changed by MSG treatment in 1K1C rats
(Correa and Saavedra, 1992). Interestingly, MSG seems to increase susceptibility to
weight gain in the SHR, but this effect does not appear to be associated with changes in
leptin (Iwase et al., 2000). The vast majority of research with this model has focused on
the effects of MSG-induced obesity on the SHR (Hambley et al., 1987; Iwase et al., 2000;
Iwase et al., 1998; Mosqueda-Garcia et al., 1986; Ross et al., 1993; van den Buuse et al.,
1985).

Proposed Mechanisms of Obesity-hypertension
According to Bray, obesity-hypertension is caused by metabolic changes that are
associated with excessive fat cell growth (Bray, 2004). These changes may produce
hypertensive pressures directly as in the case of obesity-associated sympathetic nervous
system activation or they may reduce the subject’s ability to handle other hypertensive
pressures (e.g. obesity-associated endothelial dysfunction). The latter case suggests that
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models of hypertension generated by making genetically hypertensive rats obese can be
useful even when hypertension is not induced by obesity per se (e.g. DST-OZR,
SHROB).

Studies in animal models have led to the proposal of a wide array of mechanisms that
may explain obesity-hypertension. These proposed mechanisms will be briefly reviewed
in this section. Since obese hypertensives do not always exhibit all of the clustering
factors that are implicated in these mechanisms, the explanatory power of any individual
mechanism is limited. Moreover, multiple obesity-associated abnormalities may be
required in an individual before hypertension can ultimately develop.
Hyperinsulinemia/Insulin Resistance
Hyperinsulinemia has been repeatedly cited as the primary metabolic derangement
underlying the association between obesity and hypertension (Ljutic and Korsic, 1993;
Zemel, 1995). Obesity promotes insulin resistance, which is widely believed to cause
compensatory hyperinsulinemia in an effort to sustain euglycemia (Olefsky et al., 1982).
Studies indicate that insulin resistance and compensatory hyperinsulinemia promote
increased sympathetic nervous system activity, renin-angiotensin system activity, and
vascular smooth muscle cell proliferation (Imazu, 2002). Both insulin resistance per se
and hyperinsulinemia have been blamed for increasing peripheral vascular resistance and
blood pressure (Zemel, 1995). Insulin resistance per se may lead to hypertension because
diminished insulin-stimulated Ca2+ ATPase activity retards the extrusion of Ca2+ from
vascular smooth muscle cells (Rocchini, 1991; Zemel et al., 1992). Also,
hyperinsulinemia may promote hypervolemia and high blood pressures by directly
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inducing renal sodium retention and elevating neural sympathetic output (Ljutic and
Korsic, 1993; Rowe et al., 1981; Zemel, 1995). On the other hand, results of other
studies suggest a very different role for insulin. For example, there is substantial
evidence to indicate insulin is actually a vasodilator (Zemel, 1995). Insulin has been
reported to promote NO production and have antihypertensive effects in Zucker diabetic
rats (Kawaguchi et al., 2001).

Recently, attention has shifted away from the notion that diminished insulin action on the
vascular endothelium can explain hypertension. One reason is that mice lacking insulin
receptors in the vascular endothelium have reduced blood pressures, even on a high-salt
diet (Nandi et al., 2004). Hall et al. (2003) have argued that the kidney is the primary
long-term controller of blood pressure in obesity-hypertension, and attention has turned
to the direct sodium retaining effects of insulin on the kidney. The mechanism for this
direct effect is not known, but insulin appears to increase sodium reabsorption in the
distal tubule and decrease it in the proximal tubule (Stenvinkel et al., 1992). Overall, the
net effect of insulin is to promote sodium reabsorption and salt-sensitivity of blood
pressure (Sechi, 1999). Nevertheless, studies by Hall et al. (1993; 1992) suggest that the
effects of insulin may be insufficient to produce chronic hypertension.
Hyperleptinemia/Selective Leptin Resistance
The fact that obese Koletsky and Zucker rats become hypertensive, despite a reduced
ability or complete inability to respond to leptin, suggests that leptin is not required for
obesity and hypertension to associate. Nonetheless, there is growing evidence that leptin
may function as a pathophysiological link between obesity and hypertension (Mukherjee
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et al., 2006). For example, transgenic mice that overexpress leptin have increased blood
pressure relative to wild-type controls, despite having a lower body weight (Aizawa-Abe
et al., 2000).

Leptin is an appetite-regulating cytokine that is secreted from white adipose tissue in
proportion to adipose tissue mass (Considine, 2005). As a result, the plasma
concentration of leptin is elevated distinctly in obese humans (Considine et al., 1996) and
rats (Tulipano et al., 2004). Substantial evidence from rodents indicates that leptin
chronically activates the sympathetic nervous system (SNS) and increases blood pressure
(Correia et al., 2001). Chronic hypertension that is induced by leptin can be completely
abolished by adrenergic blockade, indicating that the hypertensive actions of leptin are
mediated by adrenergic activation (Carlyle et al., 2002). In addition, leptin may also
promote hypertension by increasing reactive oxygen species and upregulating endothelin1 production (Luo et al., 2005). Just as with insulin, though, leptin triggers counteracting
hypotensive mechanisms which obfuscate its overall effect on blood pressure. Leptin
induces endothelium-dependent vasorelaxation (Kimura et al., 2000; Lembo et al., 2000)
and stimulates natriuresis (Jackson and Li, 1997; Villarreal et al., 1998). Leptin also
appears to elevate NO metabolites in the plasma, suggesting that its hypotensive actions
may be NO dependent (Beltowski et al., 2002; Fruhbeck, 1999).

Selective leptin resistance has been suggested as the causative factor for metabolic and
cardiovascular dysfunctions associated with obesity, but the mechanisms that lead to this
resistance are still unknown (Ren, 2004). If tissue resistances to leptin are specific for its
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hypotensive actions but not its sympathoexcitatory actions, then leptin could potentially
induce hypertension. In this regard, Rahmouni et al. (2005) have demonstrated that
obese mice are resistant to the metabolic effects of leptin, while the stimulatory effect of
leptin on renal sympathetic nervous activity is still preserved.
Sympathetic nervous system
It has been hypothesized that obesity may activate the sympathetic nervous system
(SNS), a prohypertensive influence, in order to reduce or prevent further weight gain
(Landsberg, 1992). This seems like a plausible method by which the body could expend
excess energy and thereby diminish fat accumulation. As attractive as this hypothesis is,
it has not been consistently supported by reports of SNS activity in obesity (Hsueh and
Buchanan, 1994; Young and Macdonald, 1992). Substantial evidence now exists
supporting several opposing views: (1) individuals develop obesity as a result of
dysfunctionally lowered SNS activity, (2) SNS activity is increased to compensate for
obesity (promoting hypertension) and (3) SNS activity is not changed in obese
individuals (Young and Macdonald, 1992). The discrepancies may be due to how and
where SNS activity is assessed because there is considerable heterogeneity in
sympathetic outputs to different organs (Hall et al., 2003a). Hall et al. (2003a) believe
that renal sympathetic activity, which has been shown to increase in obese subjects, is the
primary pathway by which sympathetic nervous activity leads to chronic hypertension.
Esler, however, has shown that increased renal sympathetic activity is not sufficient to
produce hypertension in obese patients (Esler, 2000). Still yet, increased sympathetic
activity may be required in conjunction with other sodium retaining derangements in
order for chronic hypertension to develop (Esler, 2000). In conclusion, the effect of
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obesity on the SNS varies considerably for reasons that are not clear, even though leptin
and insulin, which are both elevated in obesity, apparently stimulate the SNS.
Nitric Oxide (NO)
Nitric oxide (NO) function plays at least two important roles in blood pressure regulation.
First, NO has a well known role in endothelial regulation of vascular tone. Disturbance
of this physiological role could result in increased peripheral resistance, which is
characteristic of all known forms of human and experimental hypertension (Kunes et al.,
2004). Secondly, NO helps maintain sodium and water balance by acting as a key
signaling molecule in pressure natriuresis, a key long term determinant of blood pressure
(Evans et al., 2005). The exact role of nitric oxide in mediating pressure natriuresis, as
well as other aspects of pressure natriuresis, is still poorly understood (Evans et al.,
2005).

NO metabolism may be dysregulated by metabolic factors associated with obesity,
including leptin resistance and insulin resistance. Studies have shown that NO
production is increased by both leptin (Beltowski et al., 2002) and insulin (Steinberg et
al., 1994) through the activation of phosphatidylinositol 3-kinase (Kim et al., 2000; Zeng
et al., 2000). In insulin and leptin resistant states, however, leptin and insulin may be
incapable of producing this effect (Jiang et al., 1999). Thus, selective insulin and leptin
resistance might increase susceptibility to hypertension by inhibiting NO production but
not the sympathoexcitatory actions of insulin and leptin. There is now extensive
evidence indicating that the SNS and NO are typically well balanced counterparts of

24

blood pressure regulation and that this balance is altered in experimental hypertension
(Kunes et al., 2004).

Obesity is also associated with oxidative stress, which may be due to extended
postprandial hyperlipidemia and/or hyperglycemia (Dandona et al., 2001). Obese
humans have increased levels of oxidative stress and this is ameliorated by diet restriction
and weight loss (Dandona et al., 2001). Oxidative stress can lead to increased
deactivation of NO, which may promote hypertension (Kunes et al., 2004).
Kidney Compression
Another mechanism which may explain obesity-hypertension is obesity-induced kidney
compression that results in increased intrarenal pressure (Hall et al., 1998). This
compression may be produced by intra-abdominal pressure increases (Bloomfield et al.,
2000) and kidney encapsulation by retroperitoneal adipose tissue (Hall et al., 2002). In
addition, obesity might also exacerbate kidney compression by promoting extracellular
matrix expansion (Henegar et al., 2001; Kasiske et al., 1985). If the loops of Henle and
vasa recta are compressed by mounting intrarenal fluid hydrostatic tissue pressure, then
tubular water and sodium reabsorption could be increased (Hall et al., 2002). This might
explain why abdominal obesity bears a high relative risk for hypertension, but it does not
account for the rapid increase in arterial pressure that occurs with weight gain (Hall et al.,
2003a).
Renin-Angiotensin System (RAS)
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Some components of the renin-angiotensin system are noticeably activated in obese
individuals, despite its association with sodium retention and plasma volume expansion.
Plasma aldosterone, angiotensinogen, angiotensin-converting enzyme activity, and
plasma renin activity have all been reported to be elevated in obesity-hypertension (Hall
et al., 2002; Sharma et al., 2002). A role for the RAS is further supported by studies that
show angiotensin II antagonists and angiotensin-converting enzyme inhibitors blunt
sodium retention, plasma volume expansion, and blood pressure elevation in obese dogs
and humans (Reisin et al., 1997; Rocchini, 2000).
Sodium Retention
According to Borst and Borst-de Geus, “The blood pressure will be maintained at the
exact level required for the maintenance of sodium balance (Borst and Borst-de Geus,
1963).” Extensive evidence now indicates that sodium is at least partially responsible for
producing hypertension (Altun and Arici, 2006), particularly when obesity is present
(Antic et al., 2003). The underlying mechanisms for this phenomenon, however, have
not been fully elucidated. Sodium retention leads to an expansion of extracellular and
blood fluid volumes, which, in turn leads to an increase in blood pressure. As described
earlier, numerous factors that are commonly found in obesity may promote sodium
retention by amplifying renal tubular sodium reabsorption. These factors include kidney
compression, RAS activation, and leptin-, insulin-, or free fatty acid-induced SNS
activation (Antic et al., 2003; Wofford and Hall, 2004). If obesity were to cause a
chronic increase in tubular sodium reabsorption, then the compensatory mechanism,
known as pressure natriuresis, would be activated to prevent infinite volume expansion.
In normal situations, high salt intake leads to only very slight, if any, blood volume
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expansion because of pressure natriuresis (Faber, 1996). Thus, pressure natriuresis can
normally raise sodium excretion enough to offset sodium intake with only slight increases
in blood pressure. It is unclear how the blood pressure elevations are transduced into
changes in renal sodium excretion, but they probably lead to the inhibition of tubular
sodium reabsorption because glomerular filtration rate and renal plasma flow are
autoregulated to remain constant over a wide range of blood pressures (Evans et al.,
2005). One possible explanation for obesity-hypertension is that pressure natriuresis is
impaired so that higher blood pressures are required to increase sodium excretion
sufficiently to eliminate any given level of sodium intake (Hall, 2003). Other aspects of
renal function might also contribute to obesity-hypertension. For example, renal
autoregulation may not be completely functional in obese subjects as suggested by
reports that the glomerular filtration rate is increased in obesity (Hall et al., 2001).
Renal Injury
There is substantial evidence suggesting that obesity significantly increases the risk for
renal failure, perhaps more so than hypertension (Kincaid-Smith, 2004). For example,
studies have indicated that obese patients are significantly more likely to develop
proteinuria and a progressive loss of renal function (Morales et al., 2003). In one study,
92% of clinically obese patients who underwent unilateral nephrectomy developed
proteinuria and renal insufficiency, but only 12% of nonobese patients developed these
disorders (Praga et al., 2000). The mechanisms underlying obesity-induced renal injury
are unclear, but increased caloric intake (Stern et al., 2001), hypercholesterolemia
(Maddox et al., 2002), hyperglycemia, insulin resistance and high blood pressure have
been implicated as factors (Kincaid-Smith, 2004). Extensive renal injury may be able to
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promote hypertension by interfering with the sodium-handling ability of the kidney. The
ability of the kidney to excrete sodium is directly proportion to the functional renal tissue
mass; when functional mass of the kidney is reduced to 10% of normal, excretion of
sodium at any given arterial pressure will be only 10% of normal (Faber, 1996).

Statement of Problem
It is clear that excess weight is a major contributory factor to the development of
hypertension in most patients. In fact, this well documented relationship between obesity
and hypertension has become the foundation for an entire field of research alternately
known as obesity-hypertension, obesity-induced hypertension, or obesity-associated
hypertension. In this field, rapid advances are being made in our understanding of how
obesity and hypertension are linked. Moreover, a plethora of related risk factors,
mediators, and pathways have now been identified and described. Nonetheless, the
relationships between these factors and the extents to which they promote obesityhypertension are often poorly understood. Unscrambling the various cardiovascular and
metabolic determinants of obesity-hypertension remains a persistent problem because
both obesity and hypertension typically exhibit polygenic etiologies and diet-dependent
dynamics in humans. The judicious use of appropriate animal models promises to be an
important tool in this quest. Robust animal models that represent various “clustered”
metabolic disturbances (e.g. insulin resistance) allow investigators to advance the frontier
of knowledge regarding the underlying pathophysiological relationships between obesity
and hypertension. In addition, animal models are vital tools for designing and evaluating
approaches to the treatment of obesity-hypertension.
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The purpose of the research described in this dissertation was to assess the obese Zucker
rat as a model for obesity-hypertension. One specific aim of the research project was to
determine whether obese rats were more sensitive to experimental conditions known to
induce hypertension than age- and gender-matched lean controls. This was achieved by
subjecting lean and obese rats to two experimental protocols that are known to induce
hypertension in other rodent strains: (1) the administration of DOCA-salt to
uninephrectomized rats or (2) feeding rats a moderately high fat, high salt diet. A second
specific aim of this project was to test possible mechanisms through which a high fat diet
might induce hypertension in obese rats. Primarily, renal NO pathways were investigated
to determine if dysfunction in the renal NO system may predispose obese rats to saltsensitive hypertension. Additionally, leptin and insulin were assessed in an effort to
understand their potential prohypertensive roles in obese Zucker rats given a high fat diet.
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CHAPTER II

Increased Sensitivity of The Obese Zucker Rat to Deoxycorticosterone-Salt-Induced
Hypertension
A Manuscript Published in The Journal of Hypertension
November 2002, Volume 20, Issue 11, Pages 2247-55
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Abstract

Objective: The objective of this study was to test the hypothesis that obesity increases
the sensitivity of rats to experimentally induced hypertension.

Design and Methods: To induce hypertension, unilaterally nephrectomized lean and
obese Zucker rats were injected with 25 mg/kg of deoxycorticosterone acetate (DOCA)
twice weekly for 5 weeks and given 1% NaCl to drink. Unilaterally nephrectomized
control rats were injected with vehicle and drank tap water. Systolic blood pressure (SBP)
was measured by the tail cuff method. Renal histology and urinary albumin excretion
were used to assess the effects of the experimental treatment on the kidney.

Results: Obese rats exhibited a significant rise in SBP four days after the start of DOCAsalt treatment. In contrast, SBP of DOCA-treated lean rats was not significantly elevated
from pretreatment measurements until day 22. Moreover, SBP was significantly higher
during the plateau phase of blood pressure development in obese DOCA-salt treated rats
(196 mm Hg) than in correspondingly treated lean rats (150 mm Hg). Both obesity and
DOCA-salt treatment promoted glomerulosclerosis and mild tubulointerstitial damage in
the kidney with DOCA-salt treatment exacerbating the effect of obesity. Urinary albumin
excretion was significantly greater in obese control rats compared to lean controls and in
DOCA-treated obese rats relative to vehicle-treated obese rats.
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Conclusion: Results of this study indicate that Obese Zucker rats are more sensitive to
mineralocorticoid-induced hypertension than lean rats. This study provides experimental
evidence supporting the epidemiological findings that obesity is a risk factor for the
development of hypertension.

Key words: deoxycorticosterone acetate, hypertension, kidney, Obese Zucker Rat,
obesity-associated hypertension
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Introduction
Obesity is a significant risk factor for diseases such as hypertension, type II diabetes,
coronary heart disease and a number of other conditions that adversely affect one’s health
(Pi-Sunyer, 1993). Consequently, it is becoming an increasingly important health issue in
developed countries where the incidence of this condition has risen dramatically over the
past few decades (Kuczmarski et al., 1994; Mokdad et al., 1999; WHO, 2000).

The link between body weight and blood pressure is well known and has been clearly
documented in numerous epidemiological studies (Chiang et al., 1969). Evidence from
these studies indicates that overweight and obese individuals have a higher risk of
developing hypertension than lean individuals of the same age and gender, with the
prevalence of hypertension increasing in proportion to the degree of overweight (Kannel
et al., 1967).

To fully elucidate the mechanism(s) through which obesity can predispose an individual
to the development of hypertension, suitable animal models are required. One animal
model that has received considerable attention in this arena is the obese Zucker rat. Blood
pressures of lean and obese rats have been compared in multiple studies with varied
results. Some investigators have reported that there is no difference between blood
pressures of lean and obese rats (Auguet et al., 1989; Bunag and Barringer, 1988; Lavaud
et al., 1996; Levin et al., 1984; O'Donnell et al., 1985; Pamidimukkala and Jandhyala,
1996; Pawloski et al., 1992; Todd and Abernethy, 1986) whereas others have concluded
that blood pressure in the obese rat is elevated relative to its age- and sex-matched lean
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counterpart (Alonso-Galicia et al., 1996; Carlson et al., 2000; Kasiske et al., 1985; Kurtz
et al., 1989; Paradise et al., 1985; Wickler et al., 1982; Zemel et al., 1990). The fact that
elevated blood pressures can be recorded for the obese Zucker rat in some laboratories
but not in others when measurements were made under comparable conditions may
indicate that these animals have labile blood pressure regulatory mechanisms that are
sensitive to subtle differences in environment and/or experimental protocol. In fact,
alterations in cardiovascular regulatory mechanisms of the obese rat that could ultimately
contribute to a rise in blood pressure were described in two of the above studies reporting
undetectable differences in blood pressure between lean and obese rats (Bunag and
Barringer, 1988; Pamidimukkala and Jandhyala, 1996). Lability with respect to blood
pressure control could make the obese rat more susceptible to the development of
hypertension if this animal is exposed to an appropriate environmental stimulus.

The objective of the present study was to demonstrate experimentally that obesity is a
risk factor for the development of hypertension by subjecting lean and obese Zucker rats
to a stimulus known to induce hypertension and assessing the responsiveness of the two
groups. Data from experiments using mineralocorticoid-induced hypertension indicate
that (1) the obese Zucker rat develops hypertension more rapidly than its lean counterpart
and (2) the magnitude of the hypertensive response is much greater in obese rats than in
lean rats.

Methods
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Animals. Female obese (fa/fa) and lean (Fa/?) Zucker rats were purchased from Charles
River Laboratories (Wilmington, MA) at 8 weeks of age and housed in the Marshall
University Animal Resources Facility in plastic cages with wood chip bedding in rooms
having an ambient temperature of 23 + 2o C and a 12-hour light/dark cycle. All
procedures using rats were approved by the Marshall University Institutional Animal
Care and Use Committee.

Deoxycorticosterone acetate (DOCA)-salt hypertension. Nine-week-old lean and obese
rats were unilaterally nephrectomized under ketamine HCl-xylazine (45:5 mg/kg)induced anesthesia. During this procedure, Marshall University Animal Resources
Facility guidelines were strictly adhered to for aseptic surgery on rodents. Following a
recovery period of two weeks, control blood pressure measurements were obtained twice
weekly over an interval of two weeks. Then DOCA (25 mg/kg), suspended in corn oil,
was administered twice weekly via subcutaneous injections to one group of lean and one
group of obese rats for a period of five weeks. During the treatment period, 1% NaCl was
added to the drinking water of the DOCA-treated rats. Unilaterally nephrectomized
control lean and obese rats were injected with vehicle (corn oil) only and were given tap
water to drink. All rats had free access to Purina rat chow.

Systolic blood pressure was measured on conscious rats using a programmed
electrosphygmomanometer with a pneumatic pulse transducer and tail cuff (NarcoBiosystems, Houston, TX). Practice blood pressure measurements were obtained during
the week prior to the measurement of control blood pressures so that the rats could
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become familiar with the technique. To alleviate any stress associated with the
environment and/or protocol, the environmental conditions in the recording room and the
techniques for handling the rats and measuring blood pressure were carefully controlled.

Measurement of urine albumin. After five weeks of DOCA treatment, control and
DOCA-treated rats were placed in individual metabolic cages for a 24-hour urine
collection. The 24-hour sample was obtained after the rats were allowed to adapt to the
metabolic cage for a 24-hour period. Urine proteins were separated by one-dimensional
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis using a 5% stacking
gel and a 10% separating gel. Prior to electrophoresis, urine samples were diluted with
saline so that the density of the resultant band would fall within the linear portion of a
curve prepared by using albumin standards. A 5 microliter aliquot of each diluted sample
was mixed with 20 microliters of sample buffer containing 62.5 mM Tris-HCl (pH 6.8),
2% SDS, 10% glycerol, 5% 2-mercaptoethanol and 0.0025% bromophenol blue and
heated at 95 oC for 5 minutes. Ten microliter aliquots of the mixture were then loaded
onto the gel. Two lanes on each gel were loaded with 10 microliters of an albumin
standard (2 mg/ml). Gels were run at 60 mA until the bromophenol blue dye front
reached the bottom of the gel (approximately 1 hour) using a Bio-Rad Mini-Protean II
Electrophoresis Cell. After electrophoresis the protein bands were stained with silver
stain using a Silver Stain Plus kit (Bio-Rad, Richmond CA) according to the
manufacturer’s instructions. Gels were placed in cellophane membranes and dried
overnight in a drying frame. Subsequently, protein bands were quantified using a
Molecular Dynamics Personal Densitometer. To normalize data from multiple gels, the
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density of a given lane was expressed as a function of the albumin standard for that gel.
Results are expressed in arbitrary densitometric units times the dilution factor of the
sample.

Histology. At the end of an experiment, the rats were deeply anesthetized with a ketamine
HCl-xylazine mixture (45:5 mg/kg) and euthanized by exsanguination via cardiac
puncture. Kidneys were removed by dissection and fixed overnight in 10% buffered
formalin. Following fixation, coronal sections of the kidneys were subjected to standard
processing and embedded in paraffin. The sections were cut at 2 microns and stained with
hematoxylin and eosin (HandE). Additional sections were cut at 4 microns and stained
with periodic acid-Schiff (PAS). The slides were reviewed without knowledge of the
experimental groups. The methods of Dworkin, Feiner and Randazzo (Dworkin et al.,
1987) were followed for the quantitative assessment of the glomeruli and a mesangial
expansion score was obtained for each rat. Twenty-five glomeruli were examined in each
section and the amount of mesangial expansion was graded according to the following
scheme: “1” if of normal area, “2” if mildly increased in area, “3” if moderately increased
in area and “4” if markedly increased in area. Tubular involvement was assessed semiquantitatively with a determination of cast formation and the amount of tubular atrophy
and dilatation. Both the resulting cast score and the tubular index were determined by
counting the percent of tubules with casts or tubular dilatation and /or atrophy per 25 high
power fields in each subject. Both determinations were scored using the following
schema: “1” if 0-25% of tubules were involved, “2” if >25-50% of tubules were involved,
“3” if >50-75% of tubules were involved, and “4” if >75-100% of tubules were involved.
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Statistics. Data are expressed as means ± SEM. Statistical analysis was performed using
Sigma Stat statistical software (Jandel Corporation, San Rafael, CA). Differences among
the means of different groups were assessed by two way analysis of variance followed by
a Tukey test. A Dunnett’s test was used following two way analysis of variance of blood
pressure data in order to compare blood pressure changes in a given group with
pretreatment measurements. P values of 0.05 or less were interpreted as being statistically
significant.

Results
At the start of the study, systolic blood pressures (SBP) for vehicle-treated unilaterally
nephrectomized lean and obese rats were essentially the same (122 ± 3 and 127 ± 2
mmHg, respectively). DOCA-salt-treated obese rats exhibited a significant rise in SBP
compared to their pretreatment values as early as 4 days after the start of DOCA-salt
treatment (Figure 2.1A). When these blood pressure measurements were compared to the
obese control group, differences in SBP reached significance at day eight. In contrast,
systolic blood pressure of DOCA-salt-treated lean rats was not significantly elevated
from pretreatment measurements until day 22 (Figure 2.1B). Moreover, the magnitude of
blood pressure elevation during the plateau phase of blood pressure development, was
significantly greater in the obese group (196 mmHg) compared to the lean group (150
mmHg). Because DOCA was administered on the basis of body weight (25 mg/kg)
during the first experiment, obese rats received more DOCA than their lean counterparts.
To control for this, obese rats were given only as much DOCA as the lean rats in a
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subsequent experiment. This relative reduction in the administered amount of DOCA did
not affect the time of onset or magnitude of the blood pressure response in the obese
animals (Figure 2.2).

At the onset of DOCA-salt treatment, obese rats weighed twice as much as age- and
gender-matched lean rats (427 ± 5 g versus 217 ± 2 g respectively). During the 5-week
treatment period, vehicle treated lean rats gained an average of 21.5 ± 3.1 g whereas the
vehicle-treated obese group gained an average of 53.3 ± 6.1 g. The gain in body weights
appeared to be unaffected by DOCA-treatment in lean rats (Figure 2.3). In contrast,
DOCA-treatment did affect weight gain in the obese group: after an initial gain of 12
grams during the first week of treatment, there was no further gain in weight for the
remainder of the study (Figure 2.3). By week 5, approximately half of the rats in the
DOCA-treated obese group were losing weight. This resulted in a mean weight for the
group that was about 24 grams lower than the peak weight attained at week one.

Sections of the kidney were examined from both control and DOCA-treated lean and
obese rats. Dramatic morphologic changes were noted in the glomeruli of vehicle-treated
uninephrectomized obese rats (Figure 2.4b) compared to vehicle-treated lean rats (Figure
2.4a). These changes became more pronounced when obese rats were treated with DOCA
(Fig.4e). While focal glomerulosclerosis was present in vehicle-treated obese rats, upon
DOCA treatment, many glomeruli developed global glomerulosclerosis with almost
complete replacement with eosinophillic, hyalinized material that was PAS positive.
Moreover, glomerular changes in obese DOCA-treated rats were characterized by
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prominent expansion of the mesangial matrix and increased mesangial cellularity. To
assess the glomerular involvement, a semi-quantitative mesangial matrix expansion score
was determined. In vehicle-treated uninephrectomized animals, there was a significant
increase in the mesangial matrix score of kidneys from obese rats compared to lean rats
(Table 2.1). In addition, DOCA-salt treatment also increased matrix scores in both lean
and obese animals. Although the amount of matrix expansion in kidneys from DOCAtreated obese rats was quite dramatic relative to kidneys from DOCA-treated lean rats,
analysis of the matrix scores did not reach statistical significance due to the variability
both within an individual kidney and between animals.

In addition to the observed glomerular changes, tubular changes were also prominent in
the DOCA-treated obese rats. These changes were characterized by a thickening of the
tubular basement membranes, markedly dilated tubules with PAS-positive casts, and
tubular atrophy with flattening of the tubular epithelial cells. Although some mild cast
formation and tubular atrophy was noted in the kidneys of vehicle-treated obese rats,
prominent tubular cast formation along with tubular dilatation and atrophy were present
upon DOCA administration (Figure 2.4f). In contrast, while the lean DOCA-treated
subjects showed some tubular changes, they were much less pronounced than that seen in
the obese animals (Figure 2.4d). Separate scores were obtained for cast formation and for
the development of tubular atrophy and dilatation. Differences between lean and obese
controls and lean controls and DOCA-treated lean rats for both parameters were minor
and statistically insignificant. In contrast, both the tubular index and the cast score for
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kidneys from DOCA-treated obese rats were elevated significantly relative to vehicletreated obese rats and DOCA-treated lean rats (Figure 2.5).

As a functional correlate to the histological evaluations, urine albumin content was
measured for rats in all four experimental groups. Figure 2.6 is representative of the gels
that were used to assess urine albumin concentration. Results of all the gels that were run
are summarized in Figure 2.7A. This figure shows that the concentration of albumin in
the urine of obese rats is greater than that of lean rats both in the presence and absence of
DOCA-salt treatment. In addition, when total albumin excretion was determined using
24-hour urine volumes (Figure 2.7B), additional findings were highlighted: (1) DOCAsalt treatment significantly increased total albumin excretion in both lean and obese rats
relative to their vehicle-treated counterparts and (2) albuminuria resulting from DOCAsalt treatment was significantly greater in obese rats than in the lean rats. Urine albumin
content of the different treatment groups was consistent with their respective mesangial
matrix scores (Table 2.1).

Discussion

It has been suggested that the obese Zucker rat may be a good model for the study of
obesity-associated hypertension (Kurtz et al., 1989). This idea is supported by data from a
number of laboratories that indicate the blood pressure of obese Zucker rats is elevated
relative to lean rats (Alonso-Galicia et al., 1996; Carlson et al., 2000; Kasiske et al.,
1985; Kurtz et al., 1989; Paradise et al., 1985; Wickler et al., 1982; Zemel et al., 1990). In
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some of these studies, differences in blood pressure, although statistically significant,
tended to be modest with little evidence of overt hypertension in animals expressing the
obese phenotype. In other studies, obese rats exhibited borderline hypertension with
systolic blood pressures in the range of 145-155 mmHg. This was especially the case
when measurements were made in older animals (Kasiske et al., 1985; Paradise et al.,
1985). In contrast, other investigators, using similar experimental conditions, have been
unable to detect differences in the resting blood pressure of lean and obese Zucker rats
(Auguet et al., 1989; Bunag and Barringer, 1988; Lavaud et al., 1996; Levin et al., 1984;
O'Donnell et al., 1985; Pamidimukkala and Jandhyala, 1996; Pawloski et al., 1992; Todd
and Abernethy, 1986). A review of these studies did not reveal any obvious factors such
as the age or gender of the animals, the vendor supplying the rats or the methodology
used to assess blood pressure that could readily explain why blood pressures were
elevated in obese rats in some studies but not in others. Differences from study to study
could have occurred because blood pressure regulation in the obese rat is more labile and,
consequently, more sensitive to subtle differences in the physiological state of the animal
or the environmental conditions under which it is maintained. The suggestion that obese
animals may be more sensitive to physiological or environmental conditions that elevate
blood pressure is consistent with the idea of obesity being a risk factor for the
development of hypertension.

In the present study, we investigated obesity as a risk factor for hypertension by
challenging lean and obese Zucker rats with a set of experimental conditions known to
induce hypertension (DOCA-salt administration to unilaterally nephrectomized rats) in
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rats and then comparing the responses of animals expressing the two different
phenotypes. The onset of hypertension in the obese rat was sudden and dramatic
compared to the response of the lean rat. Moreover, the severity of the hypertensive
response was much greater in obese rats than in lean rats as evidenced by the fact that
when the blood pressures reached a plateau during the fourth and fifth weeks of the study,
the mean blood pressure in the DOCA-treated obese group exceeded that of the DOCAtreated lean group by more than 45 mmHg. These data strongly support the conclusion
that obese rats are more sensitive to DOCA-salt treatment than their lean counterparts.
The extreme sensitivity of obese rats to DOCA-salt treatment was further evidenced by
the fact that many of the obese rats exhibited some of the more harmful effects of DOCAsalt hypertension early in the treatment period. When Gavras and associates (Gavras et
al., 1975) extended DOCA-salt treatment beyond the usual 4 to 5 weeks, they observed
that the rats tended to lose weight and become moribund 6 to 10 weeks after the onset of
DOCA administration. Similarly, Kretzler et al. (1994), Wada et al. (1995) and
Matsumura et al. (2000) reported deaths and evidence of stroke and neurological damage
in DOCA-salt-treated rats that were severely hypertensive. In the current study, three of
the DOCA-salt-treated obese rats experienced seizures and about half lost weight and
became moribund before the experiment was terminated at five weeks. In contrast, only
one of the DOCA-salt-treated lean rats died before the end of the experiment and none
developed seizures.

An important issue with regard to rats subjected to DOCA-salt hypertension in general
and the aging obese Zucker rat in particular is the structural and functional integrity of
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the kidney. As the obese Zucker rat ages, it exhibits progressive renal damage. Although
renal function is similar in lean and obese rats at 12 to 14 weeks of age, the obese rat is
already exhibiting a small degree of proteinuria and histological evidence of mesangial
matrix expansion at this time (Kasiske et al., 1985). By 17 weeks of age, approximately
3% of tubules from the kidney of the obese rat exhibit evidence of mild injury and 1% to
3% of the glomeruli exhibit early focal glomerulosclerosis (Magil, 1995). By 28 weeks of
age, 5% of the glomeruli in the kidney of the obese rat exhibit focal glomerulosclerosis
and there is a marked increase in urine albumin excretion. Moreover, in this age group,
rats that have been unilaterally nephrectomized for a period of 24 weeks exhibit twice the
incidence of focal glomerulosclerosis as two-kidney obese rats (Kasiske et al., 1989). As
rats continue to age, there is an increased incidence of focal glomerulosclerosis and
tubular damage. Kasiske et al. (1985) have reported that almost 32% of glomeruli from
kidneys of 68-week-old obese rats exhibit focal glomerulosclerosis compared to just 5%
of glomeruli from kidneys of age-matched lean rats. In addition, kidney sections from 51
and 61-week-old obese rats have areas with markedly dilated tubules, some of which
contain PAS-positive casts (Shimamura, 1983). Casts are rare in the tubules of younger
obese Zucker rats (Magil, 1995).

In the present study, rats were 9 weeks of age at the start of an experiment and 18-weeksold at its conclusion. At 18 weeks of age, one would predict a small degree of glomerular
and tubular damage in the kidneys of vehicle-treated obese rats and significant
albuminuria relative to that recorded for vehicle-treated lean rats. This is consistent with
our observations.
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Changes in renal structure induced by chronic DOCA-salt treatment in some strains of rat
are qualitatively similar to those observed in the kidney of the aging obese Zucker rat.
For example, in studies using Sprague-Dawley and Munich-Wistar rats, the kidneys from
DOCA-salt treated animals exhibited mesangial matrix expansion and glomerulosclerosis
(Dworkin et al., 1987; Kretzler et al., 1994; Shimamura, 1990). Moreover, mild tubular
damage characterized by atrophy of the tubular epithelium, tubular dilatation and the
presence of hyaline casts has been observed in response to DOCA-salt treatment (Kim et
al., 1994; Matsumura et al., 2000). In the present study, the renal effects of DOCA-salt
treatment in the lean Zucker rat were comparable to those reported for other stains of rat:
a modest increase in the mesangial matrix and mild tubular dilatation. In contrast, the
effects of DOCA-salt treatment on the kidney of the obese Zucker rat were far more
severe. In many glomeruli, global glomerulosclerosis was evident with the glomerulus
being replaced by hyaline material. DOCA-salt effects on renal tubules were even more
remarkable: many tubules in the obese rat kidney were markedly dilated, had a flattened
epithelial lining and were filled with casts. Moreover, the striking structural changes in
the kidney of the DOCA-salt treated obese rat were paralleled by an equally dramatic
increase in the level of albuminuria. These observations suggest that DOCA-salt
treatment may be accelerating the progressive renal injury that occurs in the aging obese
Zucker rat.

One problem associated with research involving genetic models of obesity is that it is
often difficult to determine whether the observed effect is due to obesity per se or to the
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expression of the mutated gene. In the obese Zucker rat, obesity is due to a mutated leptin
receptor (Chua et al., 1996; Takaya et al., 1996). Leptin is a peptide produced by adipose
tissue that plays an important role in the long-term regulation of food intake and energy
expenditure. It has been suggested that leptin may also play a role in blood pressure
regulation and possibly in the development of hypertension. When administered to
normotensive rats, leptin causes a modest increase in blood pressure (Carlyle et al., 2002;
Dunbar et al., 1997; Fruhbeck, 1999; Shek et al., 1998), an effect that may be due to a
leptin-induced increase in sympathetic activity (Dunbar et al., 1997; Hall et al., 2001).
The obese Zucker rat, which has an abnormal leptin receptor, appears to be resistant to
the effect of leptin on sympathetic activation (Haynes, 2000) and blood pressure
elevation (Fruhbeck, 1999). It is this resistance to the effects of leptin that could make the
obese Zucker rat more susceptible to DOCA-salt hypertension. When lean Zucker rats are
given an IV bolus injection of leptin, there is a marked increase in urine sodium excretion
(Villarreal et al., 1998). This natriuretic effect of leptin is greatly attenuated in the obese
Zucker rat (Villarreal et al., 1998). If leptin is shown to play a significant regulatory role
in allowing an animal to adjust to an increased sodium load, then resistance to this effect
could make the obese rat more susceptible to the development of DOCA-salt
hypertension. Further studies are needed to test this hypothesis and to determine whether
the increased susceptibility of the obese Zucker rat to DOCA-salt hypertension is due to
obesity per se or the consequence of a mutated leptin receptor.

In conclusion, results of this study indicate that young obese Zucker rats, with resting
systolic blood pressures that are indistinguishable from age- and sex-matched lean rats,
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may be more sensitive to conditions that promote the development of hypertension than
their lean counterparts. Furthermore, these results support the conclusion of others that
the obese Zucker rat may be a useful model for the study of obesity-associated
hypertension.
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Figures and Tables

Table 2.1. Mesangial matrix scores of vehicle
and DOCA-salt treated lean and obese Zucker
rats.
Group

Mesangial Matrix Score

Lean 1-kidney Control
Lean 1-kidney DOCA

1.36±0.17
2.26±0.16

Obese 1-kidney Control
Obese 1-kidney DOCA

2.40±0.17
2.98±0.15

Data are expressed as the mean ± SEM for each
group. The mesangial matrix score is
significantly affected (p<0.05) by both the
phenotype and DOCA-salt treatment.
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Figure 2.1. Systolic blood pressure (SBP) in obese (A) and lean (B) rats before and during DOCAsalt treatment. The arrow indicates the time when DOCA-salt treatment was initiated (Day 0).
Nineteen obese rats and 13 lean rats were injected twice-weekly with DOCA (25mg/kg) in corn oil
and given 1% NaCl in their drinking water. Sixteen obese rats and 13 lean rats were injected with
vehicle (corn oil) and given tap water to drink. * P<0.05 compared to pretreatment SBP for that
group.
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Figure 2.2. Effects of reducing the amount of DOCA administered to obese Zucker rats on SBP. In
this experiment, age-matched lean and obese rats were given the same absolute amount of DOCA.
The quantity of DOCA administered to the obese rats (N=7) was based upon the weight of the agematched lean rats. The magnitude of the blood pressure response and time required to cause a
significant elevation in blood pressure were essentially the same as for obese rats given DOCA at a
dose of 25 mg/kg. *P<0.05 compared to both pretreatment blood pressures for the reduced-DOCA
obese group and blood pressures for age-matched vehicle-treated obese rats.
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Figure 2.3. Changes in body weights of lean and obese rats in response to DOCA-salt treatment. Rats
were injected twice weekly with DOCA (25 mg/kg) in corn oil and given 1% NaCl in their drinking
water. Vehicle-treated rats were injected twice weekly with corn oil only and given tap water to
drink. *P<0.05 compared to vehicle treated rats at the same time interval.
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Figure 2.4. Light micrographs of hematoxylin and eosin prepared kidney sections at 600X
magnification. (a) Lean control kidney showing essentially normal glomeruli and tubules. (b) Obese
control kidney showing a mild increase in the mesangial matrix and some tubular dilatation. (c) Lean
DOCA-treated kidney showing a glomerulus with a moderate increase in the mesangial matrix and
some surrounding mild tubular dilatation. (d) Lean DOCA-treated kidney showing mild tubular
dilatation. (e) Obese DOCA-treated with severe global glomerulosclerosis with the glomerulus
replaced by amorphous hyaline material. (f) Obese DOCA-treated kidney showing very dilated
tubules filled with casts and showing atrophy with flattening of the tubular lining epithelium.
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Figure 2.5. Tubular indices (A) and cast scores (B) for kidneys from DOCA- and vehicle-treated lean
(Ln) and obese (Ob) Zucker rats. Each bar represents the mean and each bracket the SEM of scores
from 5 to 7 different kidneys in each group. *P<0.05 compared to the vehicle-treated obese group;
+
P<0.05 compared to the DOCA-treated lean group.
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Figure 2.6. SDS-PAGE gel showing urine albumin content. Urine samples were subjected to SDSPAGE and the gels were stained with silver stain as described in the methods section. Lanes 1 and 8
contained an albumin standard (2 mg/ml), lanes 2 and 4 contained urine from DOCA-treated lean
rats, lane 3 urine from a vehicle-treated lean rat, lanes 5 and 7 urine from DOCA-treated obese rats
and lane 6 urine from a vehicle-treated obese rat.
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Figure 2.7. Albumin excretion in DOCA- and vehicle-treated lean (Ln) and obese (Ob) Zucker rats.
Aliquots of 24-hour urine samples were diluted and subjected to SDS-electrophoresis and
densitometric analysis. Urine albumin concentration, expressed as relative density in panel A, was
determined by comparing the density of the albumin fraction of each urine sample with that of a
known concentration of albumin standard run on the same gel. In panel B, the total amount of
albumin excreted in a 24-hour period was obtained by multiplying the relative density of the albumin
band times the 24-hour urine volume. Each bar represents the mean and each bracket the SEM of
urine samples from 6 different rats. *P<0.05 compared to urine samples of lean rats subjected to the
same treatment; +P<0.05 compared to the vehicle-treated group of the same phenotype.
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Abstract
The objective of this study was to assess the progression of renal damage in obese Zucker
rats in response to deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Renal
damage was evaluated by light microscopy and urine analysis at weekly intervals during
the developmental phase of DOCA-salt hypertension and once during the plateau phase
42 days after the onset of treatment. Decreased tubular function was evident by day 8, as
indicated by a significant increase in urine N-acetyl-β-D-glucosaminidase activity and
glucose excretion. The tubular index, a measure of tubular damage, was significantly
elevated by day 15 and continued to increase throughout the experiment. Glomerular
damage, which was evident by day 8, was followed by increased urine albumin excretion
by day 15. Only a few sclerotic glomeruli were apparent before the plateau phase;
however, by day 42, approximately 50% of the glomeruli were sclerotic. Hyperplastic
vascular changes were mild at day 8 and slowly increased in severity during the
developmental phase. By day 42 the vascular changes were quite dramatic with some
vessels being so hyperplastic that their lumens were almost occluded. Overall, these
findings show progressive changes in renal structure and function that begin as early as
day 8 and increase over time until dramatic changes are present at day 42, resulting in an
end stage kidney.
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Introduction
Data from multiple national surveys clearly demonstrate a dramatic rise in the incidence
of obesity (a body mass index in excess of 30) in the United States over the past 25 years
(Flegal et al., 1998; Flegal et al., 2002; Mokdad et al., 1999). Because obesity is a risk
factor for multiple disorders such as type 2 diabetes, coronary heart disease, and
hypertension (Pi-Sunyer, 2002), the progressive increase in the incidence of obesity has
become a serious health concern.

Obesity is a well-established risk factor for hypertension with the incidence of
hypertension for obese adults being almost three times that observed for non-obese
individuals (Van Itallie, 1985). The consequences of chronic hypertension include serious
end organ damage resulting in cardiac and vascular hypertrophy, stroke and/or renal
damage. In the kidney, hypertension may initiate renal damage or it may promote the
progression of previously established renal disease (Klahr et al., 1988). Hypertensionassociated renal damage has been demonstrated in both clinical (Brazy et al., 1989; Klag
et al., 1996) and experimental studies (Dworkin et al., 1984).

While much attention has been focused on the role of hypertension in progressive renal
damage, less is known about the effects of obesity per se on renal structure and function.
A recent retrospective study suggests that obesity by itself may promote the development
of focal glomerulosclerosis and glomerulomegaly (Kambham et al., 2001). The
glomerular changes observed in renal biopsies from this study were similar to those
observed by Kasiske et al. (1985) and Shimamura (1983) in their work with the mature
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obese Zucker rat, a genetically obese animal that has been used as an experimental model
to study obesity-associated glomerulosclerosis (Gassler et al., 2001; Kamanna and
Kirschenbaum, 1993; Kasiske et al., 1991; O'Donnell et al., 1985).

The obese Zucker rat may also be useful as an experimental model to assess the
interaction between obesity and hypertension in the promotion of progressive renal
damage. We have recently reported that obese Zucker rats exhibit an enhanced sensitivity
to deoxycorticosterone-salt (DOCA-salt)-induced hypertension. In this study, systolic
blood pressure rose more rapidly and the magnitude of the hypertensive response was
significantly greater in obese rats treated with DOCA-salt than in correspondingly treated
age- and gender-matched lean rats (Morrison et al., 2002). Moreover, marked
glomerulosclerosis and tubulointerstitial damage were evident in kidneys of hypertensive
obese rats at the end of the study whereas DOCA-salt treated lean rats exhibited only
modest changes in renal histology.

The objective of the present study was to use biochemical and morphologic measures to
assess the temporal pattern of change in the kidney of obese Zucker rats in response to a
course of DOCA-salt administration. Biochemical abnormalities reflective of both tubular
and glomerular damage were seen early and progressively during the developmental
phase of the hypertensive response. Likewise, changes in tubular, glomerular and
vascular morphology occurred early and continued to increase in extent and severity over
the course of the study. The glomerular damage involved the development of mesangial
hypercellularity with an endpoint of glomerulosclerosis. Progressive changes in the
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tubules included tubular dilatation, atrophy of tubular epithelial cells and cast formation.
The vascular changes were quite prominent with the development of hyperplastic
arteriolosclerosis that increased dramatically in severity over time, culminating in the
appearance of plexiform lesions and nearly complete vessel occlusion by the end of the
study.

Materials and Methods
Animals. Eight-week-old female obese (fa/fa) Zucker rats were purchased from Charles
River Laboratories (Wilmington, Massachusetts, USA) and housed in the Marshall
University Animal Resources Facility in plastic cages with wood chip bedding in rooms
having an ambient temperature of 23±2 °C and a 12 h light/dark cycle. Rats were allowed
to acclimate to this facility for one week prior to being incorporated into an experimental
study. All procedures using rats were approved by the Marshall University Institutional
Animal Care and Use Committee.

Experimental procedures using animals. Nine-week-old rats were deeply anesthetized
with a mixture of ketamine HCl and xylazine (45:5 mg/kg) and then unilaterally
nephrectomized under aseptic conditions as prescribed by Marshall University Animal
Resources Facility guidelines for aseptic surgery on rodents. Following surgery, rats were
allowed to recover for a period of two weeks before being subjected to further
experimental manipulation. After the recovery period, the rats were familiarized with the
blood pressure measurement protocol for an additional week before blood pressure
measurements for the experiment were begun. Throughout the study, body weights were
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measured twice weekly and the systolic blood pressure (SBP) measured once weekly on
conscious rats by tail cuff plethysmography using a programmed
electrosphymomanometer with a pneumatic pulse transducer and tail cuff (NarcoBiosystems, Houston, Texas, USA).

Deoxycorticosterone acetate (DOCA)-salt hypertension was induced by means of
biweekly subcutaneous injections of DOCA (25 mg/kg) suspended in corn oil. During the
DOCA-treatment period, 1% NaCl was added to the drinking water. All rats had free
access to Purina rat chow throughout the study. Five randomly selected rats were not
treated with DOCA. These rats were sacrificed one day after the beginning of the DOCAsalt treatment (“Day 1”) to obtain kidneys for histological analysis.

Six days prior to the start of DOCA-salt treatment and at weekly intervals during the
developmental phase of the hypertensive response, 6 rats were placed in stainless steel
metabolic cages to measure food and water consumption and 24-hour urine output and to
collect urine for assessing renal function. The animals were given 1 day to adapt to the
metabolic cages before measurements were obtained and samples collected. Urine
samples were collected at 6- and 24-hours with the 6-hour urine sample being collected in
a cold container. Immediately upon collection, the urine samples were centrifuged and
the supernatant stored at -20o C until used for analysis.

Analytical procedures. The Bradford (Bradford, 1976) technique was used to measure
the total protein content of urine with the data being expressed as mg of protein excreted
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per 24 hours. Urine albumin levels were measured as described previously (Morrison et
al., 2002). Briefly, aliquots of a 24-hour urine sample were diluted with 0.9% NaCl and
separated by one-dimensional SDS-PAGE using a 5% stacking gel and a 10% separating
gel. Following electrophoresis, the gels were stained using a Silver Stain Plus kit (BioRad, Richmond CA) according to the instructions of the manufacturer and then dried
overnight. Protein band density was measured with a Molecular Dynamics personal
densitometer and the intensity of each protein band was expressed as a function of the
albumin standard run with that gel. Samples high in protein content were diluted with
0.9% NaCl before being subjected to electrophoresis so that their densities would fall
within the linear portion of a densitometric curve prepared with increasing concentrations
of an albumin standard. Results are expressed as arbitrary densitometric units times the
dilution factor of the individual 24-hour urine sample.

Urinary excretion of the lysosomal enzyme, N-acetyl-β-D-glucosaminidase (NAG), and
glucose were used as indices of renal tubular integrity. To remove inhibitors, urine
samples were fractionated on a Sephadex G-50 gel filtration column before being assayed
for NAG activity by means of a colorimetric assay (Roche Diagnostics, Indianapolis, IN).
NAG content is expressed in terms of mU of NAG activity in a 24-hour urine sample.
Urine glucose levels were measured using a Beckman Glucose Analyzer 2 (Beckman
Instruments, Brea, CA) with the data being expressed as mg glucose excreted per 24
hours.
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Histological methods. At weekly intervals, five randomly selected rats were deeply
anesthetized with a ketamine HCL-xylazine mixture (45:5 mg/kg) and euthanized by
exsanguination via cardiac puncture. Kidneys were removed and sliced into sections that
were fixed overnight in 10% buffered formalin. Each kidney was entirely sectioned, and
two representative sections were subjected to standard processing and embedded in
paraffin. Sections were cut at 2 µm and stained with hematoxylin and eosin (HandE).
Thin sections were utilized to enhance morphologic detail. Slides were reviewed without
knowledge of the experimental groups. Twenty-five glomeruli were examined in each
section and the amount of mesangial expansion was graded as follows: "1" if the
mesangial area was normal, "2" if the area was mildly increased, "3" if it was moderately
increased, and 4 if it was markedly increased. Mesangial expansion scores were
calculated for each rat according to the procedure described by Dworkin et al (Dworkin et
al., 1987). In addition, the percentage of sclerotic glomeruli was determined by assessing
a total of 25 glomeruli in each section and counting the number of glomeruli that
demonstrated sclerosis. Tubular involvement was assessed semi-quantitatively by
determining a cast score and tubular index for each rat. Cast scores were obtained by
counting the percentage of tubules with casts per 25 high power fields and the tubular
index was determined by counting the percentage of tubules exhibiting tubular atrophy
and/or dilatation per 25 high power fields. Both determinations were scored as follows:
‘1’ if 0-25% of tubules were involved, ‘2’ if >25-50% of tubules were involved, ‘3’ if
>50-75% were involved, and ‘4’ if > 75-100% of tubules were involved.
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Statistics. Data are expressed as means ± SEM. Statistical analysis was performed using
Sigma Stat statistical software (Jandel Corporation, San Rafael, California, USA).
Following normality and equal variance testing, comparisons between groups were made
using one-way analysis of variance and, afterward, a Dunnett's test for making multiple
comparisons against the untreated control group. When sample sizes were unequal, a
Dunn's test was used instead. Three data sets failed the normality test and were subjected
to Kruskal-Wallis one-way analysis of variance on Ranks followed by a Dunn's test to
make multiple comparisons against the untreated control group. P values of ≤0.05 were
interpreted as being statistically significant.

Results
In obese Zucker rats subjected to DOCA-salt treatment, systolic blood pressure increases
progressively over a period of about 4 weeks (developmental phase) then tends to plateau
at severely hypertensive levels (Morrison et al., 2002). In the present study, changes in
the morphology of kidneys from DOCA-salt-treated obese rats were assessed at weekly
intervals during the developmental phase of hypertension and at one point two weeks
after systolic blood pressure reached a plateau. During the developmental phase, temporal
changes in renal function were also monitored.

Twenty-four hour urine output was measured at weekly intervals and, as expected,
DOCA-salt treatment caused a progressive increase in the total amount of urine excreted
beginning soon after the initial injection of DOCA on day 0 (Figure 3.1). At all time
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points after day 1, there was a significant increase in urine volume compared to the
control measurements which were collected 6 days prior to the initial administration of
DOCA. The increases in urine volume were accompanied by corresponding increases in
fluid consumption (Table 1).

Randomly selected rats were sacrificed just prior to the start of DOCA-salt treatment and
at weekly intervals thereafter. The remaining kidney was removed from each animal,
sectioned, and examined by light microscopy using HandE staining. Thin sections from
all time points were examined and significant changes were noted within the tubules.
The normal architecture of the tubules was progressively altered over time and
characterized by tubular disarray, dilatation of the tubular lumens, atrophy of the tubular
epithelium, and loss of epithelial cell nuclei (Figure 3.2). Hyaline casts were noted
within the tubules in a number of animals. Although they appeared to increase over time,
the casts were focal in distribution and were not present in all animals. For a semiquantitative assessment of tubular injury, both a tubular index and a cast score were
determined for each animal. The tubular index for kidneys from DOCA-salt-treated
obese rats began to rise as early as day 8 and increased progressively over time during the
developmental phase of the hypertensive response: statistical significance was reached by
day 15 (Figure 3.3A). Cast scores, in contrast to the tubular index, were not statistically
significant until day 42 (Figure 3.3B), although there was a trend toward increased values
beginning at day 22. Changes in tubular function were also evaluated during the
developmental phase of the hypertensive response. NAG activity, a sensitive measure of
tubular integrity (Vanderlinde, 1981), peaked in the urine of DOCA-salt-treated rats at
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day 8 and remained significantly elevated compared to untreated controls throughout the
collection period (Figure 3.4B). Another biochemical measure of tubular damage is
glucose excretion (Figure 3.4A). Urine glucose excretion was also significantly elevated
by day 8 and increased progressively throughout the collection period.

Glomerular changes were also assessed using both biochemical and morphologic
measures. Twenty-four-hour urine albumin excretion, an important measure of
glomerular function, showed a statistically significant increase beginning at day 15
(Figure 3.5B). In addition, total urine protein was measured and exhibited changes
similar to those observed for urine albumin with a significant increase being seen by day
15 (Figure 3.5A). Light microscopic review of the kidney sections revealed increased
glomerular cellularity, primarily in the mesangium, beginning as early as day 8 (Figure
3.6). This progressively increased over all time points to day 29. No sclerotic glomeruli
were observed in sections obtained from rats during the developmental phase of the
hypertensive response. To obtain a semi-quantitative measure of the increased
cellularity, a mesangial matrix score was determined. The mesangial matrix score was
significantly elevated by 8 days of DOCA-salt treatment and continued to increase
progressively throughout the developmental phase of the hypertensive response (Figure
3.7). Sclerotic glomeruli, which were not evident during the developmental phase, began
to appear at the beginning of the plateau phase. Two weeks into the plateau phase, 50%
of the glomeruli were sclerotic (Figure 3.7).
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Sections from all time points were carefully examined for vascular changes. Special
attention was paid to the afferent and efferent glomerular arterioles along with the
peritubular vessels. No vascular changes were noted in the untreated animals. Overall,
both the glomerular arterioles and peritubular vessels showed hyperplastic
arteriolosclerotic changes with treatment (Figure 3.8). These changes were characterized
by intimal thickening, caused by the proliferation of smooth muscle cells and the
concentric layering of collagen, and a progressive narrowing of the vascular lumens.
Initially, the vascular changes were mild and focal. They slowly increased in both
severity and extensiveness from day 8 through day 29 (Figure 3.8). Marked findings
were seen at day 42 with some vessels so hyperplastic that the lumen was almost
occluded. Focal fibrinoid necrosis was present in the luminal areas of the vessels;
however, the hyperplastic changes were most prominent. The hyperplastic changes were
so prominent that some vessels even formed plexiform type structures (Figure 3.8f). At
this time point, the kidneys were severely damaged in all areas and constituted an end
stage kidney.

Discussion
In the present study, DOCA-salt hypertension was used to assess temporal changes in
renal structure associated with the development of hypertension in genetically obese rats.
DOCA-salt hypertension has been used by a number of laboratories as a tool to study the
interactions between hypertension and other factors that lead to the progression of renal
disease. Janssen and associates (Janssen et al., 2003), for example, have demonstrated

67

that the Goto Kakizaki rat, a model of non-obese type II diabetes, exhibits more
pronounced proteinuria and tubulointerstitial damage when subjected to DOCA-salt
treatment than age- and gender-matched rats of the parent strain. Investigators assessing
interactions between Heymann nephritis and hypertension have also used the DOCA-salt
model of hypertension and have shown that rats immunized with a renal brush border
extract exhibit an increased sensitivity to the development of DOCA-salt hypertension, a
greater degree of glomerulosclerosis and proteinuria (Tikkanen et al., 1980) and an
enhanced production of cytokines and growth factors that are thought to promote renal
damage (Tikkanen et al., 1995) than non-immunized rats that are treated with DOCAsalt. Similarly, we have shown that obesity greatly exacerbates the hypertensive response
and the degree of end organ damage associated with the development of DOCA-salt
hypertension (Morrison et al., 2002). Compared to lean littermates, the development of
DOCA-salt hypertension is accelerated in the obese Zucker rat and the magnitude of the
hypertensive response that is attained is markedly higher. Moreover, the degree of renal
damage is significantly greater in obese rats than in lean rats.

Because they are inclined to develop renal injury in the absence of any external
manipulation, DOCA-salt-treated obese Zucker rats appear to provide a good model for
studying the interactions between two factors that independently promote the progression
of renal damage: obesity and hypertension. To this end, it has been clearly demonstrated
that the spontaneous development of glomerulosclerosis (Kasiske et al., 1985;
Shimamura, 1983) and tubulointerstitial damage (Magil, 1995) tends to occur more
frequently in Zucker rats expressing the obese phenotype than in age- and gender-
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matched lean rats. In these animals, the development of glomerulosclerosis is preceded
by a significant elevation in urine albumin excretion and mesangial matrix expansion
(Kasiske et al., 1985).

In the present study, obese Zucker rats subjected to DOCA-salt treatment exhibited
histological evidence of glomerular, tubular and vascular abnormalities early during the
developmental phase of hypertension. Mesangial hypercellularity and an enlargement of
the entire glomerular complex characterized the initial glomerular response. This was
reflected by a statistically significant increase in the mesangial matrix score by day 8 of
treatment. At this point in the experiment, the rats were exhibiting only a mild degree of
hypertension with the average systolic blood pressure for the group being 143.8 + 4.8.
The extent and severity of glomerular changes increased steadily over time. By day 29,
the mesangial matrix score reached its maximum and sclerotic glomeruli began to appear
in kidney sections. Also by day 29, the steady rise in blood pressure reached a plateau
phase characterized by systolic blood pressures in excess of 195 mmHg. It was during the
plateau phase that the number of sclerotic glomeruli increased dramatically. The
development of sclerosis is an end stage pathological response to injury in a glomerulus.
The mechanism underlying the development of glomerulosclerosis in DOCA-salt
hypertension has not been clearly defined although there is evidence that injury to the
glomerulus caused by a variety of conditions leads to the excessive production of growth
factors and cytokines by mesangial cells and the attraction of inflammatory cells that may
promote this process (Becker et al., 2001).
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Biochemical markers of the functional integrity of the glomerulus (urine albumin
excretion), and tubules (urine NAG activity and glucose excretion) were also monitored
during the developmental phase of the hypertensive response. Significant increases in
urine NAG activity and glucose excretion were evident before there was a significant
increase in urine albumin excretion, suggesting that, in the obese rat, the functional
integrity of the tubules may be compromised more rapidly during the initial phase of
DOCA-salt treatment than that of the glomeruli.

A significant rise in urine NAG activity and glucose excretion also preceded a
statistically significant increase in the tubular index. The tubular index, a calculation used
to quantify changes in tubular morphology, was significantly elevated by day 15 and
continued to rise steadily throughout the remainder of the study. In contrast, the cast
score, which measures the presence of casts in the tubules, was elevated significantly
only after the kidney had been chronically subjected (day 42 in the process) to the severe
levels of hypertension associated with the plateau phase of the hypertensive response.
This observation, coupled with the findings that cast distribution was focal and that casts
were not present in all kidneys during the developmental phase of the hypertensive
response, suggests that cast formation may be a consequence of end stage renal disease
brought on by the prolonged exposure of the kidneys to severe hypertension.

A unique feature of the present study is that we were able to observe the progression of
renal damage throughout the developmental phase and well into the plateau phase of the
hypertensive response. Comparisons of our results with other studies, however, are
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limited to those changes associated with the plateau phase because most studies that have
addressed changes in renal morphology in response to DOCA-salt administration are
typically terminated only after the plateau phase has been reached. In studies that are
terminated after 4 to 6 weeks of treatment, the effects of DOCA-salt administration on
the glomeruli, tubules and small vessels of the kidney are qualitatively similar. The extent
of the damage, however, varies from study to study with the degree of damage to the
kidney and the incidence of mortality in obese Zucker rats being comparable to the more
severe responses reported for DOCA-salt administration (Gavras et al., 1975; Kretzler et
al., 1994; Wada et al., 1995). Variations in susceptibility to DOCA salt treatment have
thus far been attributed, in part, to factors such as age (Kretzler et al., 1994; Wada et al.,
1995) or strain (Hartner et al., 2003). We have demonstrated that an obese phenotype also
has a profound impact upon the response of a rat to DOCA-salt administration. As shown
previously (Morrison et al., 2002), the degree of glomerular and tubulointerstitial damage
in the lean Zucker rat treated with DOCA-salt appears to be relatively mild. In contrast,
obese littermates of the same gender exhibit profound glomerulosclerosis,
tubulointerstitial damage and vascular injury when subjected to an identical treatment
regimen.

The progressive changes in the glomeruli and tubules beginning at day 8 and slowly
increasing at all time points during the development phase may provide a good model to
study the chronic renal changes that occur with hypertension and obesity. In contrast,
the dramatic vascular changes occurring most extensively at day 42 may provide a good
model for studying malignant hypertension. Hyperplastic arteriolosclerosis is associated
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with malignant hypertension which often occurs in patients with existing benign
hypertension. Although we did not demonstrate vascular hyaline arteriolosclerosis that
can be seen in patients with chronic hypertension, we did demonstrate changes in the
glomeruli and tubules, as noted above. The dramatic vascular changes observed at day
42, accompanied by a marked increase in both tubular and glomerular damage, suggest
that the sustained and dramatic increase in blood pressure leads to an end stage kidney.

In summary, we have used histological examination and biochemical markers to assess
renal changes associated with the development of hypertension in obese rats. By doing
so, we have observed that (1) there is evidence of renal injury very early in the
development phase of the hypertensive response when the level of hypertension is mild,
(2) the degree of renal injury increases with the rise in blood pressure during the
developmental phase, (3) the functional integrity of tubules in the kidney of the obese rat
may be more sensitive to injury induced by DOCA-salt hypertension than that of the
glomeruli, and (4) certain indices of progressive renal damage such as glomerulosclerosis
and cast formation are only evident after the plateau phase of the hypertensive response
has been reached. We conclude that the obese Zucker rat may be a good model to study
interactions between obesity and hypertension on the progression of renal damage.
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Figures and Tables

Table 3.1. Body weights, food and water consumption, and systolic blood pressure before
(day -6) and during the DOCA-salt treatment period (days 1-22).

Day

-6

1

8

15

22

380.8

394.5

410.8

423.2

416.5

(grams)

±8.6

±7.6

±8.2

±9.9

±13.7

Food Consumption

25.5

12.7

23.0

25.8

22.4

(grams/24 hours)

±1.1

±2.1

±1.5

±1.6

±0.7

Water Consumption

47.7

57.8

110.8a

150.7a

171.0a

(ml/24 hours)

±1.0

±6.8

±5.2

±12.2

±2.9

120.4

132.6

143.8a

150.5a

160.3a

±2.2

±3.6

±4.8

±5.6

±5.7

Body weight

Blood Pressure
(mmHg)
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a

p<0.05 compared to day -6. Data are expressed as the mean ± SEM for each group
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Figure 3.1. The effect of DOCA-salt treatment on urine volume. For each collection period, rats were
placed in individual stainless steel metabolic cages for 48 hours. During the last 24 hours, urine
output was measured. Urine samples were collected six days (day -6) prior to and 1 day after the
initial DOCA injection (day 0) and at weekly intervals thereafter. Each point is the mean ± SEM for
6 rats. *P<0.05 compared to urine formation on day -6.
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Figure 3.2. Histological changes occurring in the kidney tubules examined at the following time
points: A-control, B-day 8, C-day 15, D-day 22, E-day 29, and F-day 42. All pictures were taken at
600x except panel A which was taken at 400x. The lower power was utilized for the control kidneys
(panel A) to allow assessment of a larger field and confirm the lack of histological changes.
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Figure 3.3. The effect of DOCA-salt treatment on renal tubules. Tubular indices and cast scores
were determined on HandE sections of kidneys as described in the methods. Each point represents
the mean ± SEM of the tubular index (A) or cast scores (B) from 5 rats subjected to DOCA-salt
treatment for the number of days indicated on the X-axis. *P<0.05 compared to the untreated
uninephrectomized controls (Day 0).
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Figure 3.4. The effect of DOCA-salt treatment on the excretion of glucose and N-acetylglucosaminidase (NAG). Urine glucose levels (A) and NAG activity (B) were determined in 24-hour
urine samples collected six days (day -6) prior to the initial DOCA injection (day 0), one day after the
first DOCA injection and at weekly intervals thereafter. Urine NAG content is expressed in terms of
mU of NAG activity excreted in 24-hours. Each point is the mean ± SEM for 6 rats. *P<0.05
compared to glucose content or NAG activity in urine collected from rats on day -6.
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Figure 3.5. The effect of DOCA-salt treatment on protein and albumin excretion. Total protein (A)
and albumin (B) levels were measured in 24-hour urine samples obtained six days (day -6) prior to
the initial DOCA injection (day 0), one day after the first DOCA injection and at weekly intervals
thereafter. Total protein is expressed as mg of protein excreted per 24 hours. Urine albumin content
is expressed as arbitrary densitometric units per unit volume times the appropriate dilution factor
for each 24-hour urine sample. Each point is the mean ± SEM for 6 rats. *P<0.05 compared to total
protein or albumin content of urine collected from rats on day -6.
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Figure 3.6. Histological changes occurring in the glomeruli examined at the following time points: Acontrol, B-day 8, C-day 15, D-day 22, E-day 29, and F-day 42. All pictures were taken at 600x, except
panel E was taken at 400x. Note the arrow in panel a. This is highlighting a small vessel in the
control animal. Panel E was taken at a lower power to allow visualization of two glomeruli,
illustrating the mesangial proliferation present.
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Figure 3.7. The effect of DOCA-salt treatment on mesangial expansion and the formation of sclerotic
glomeruli. Mesangial matrix scores were determined on HandE sections of kidneys as described in
the methods. Each point represents the mean ± SEM of matrix scores from 5 rats subjected to
DOCA-salt treatment for the number of days indicated on the X-axis. The vertical bars represent the
percentage of sclerotic glomeruli at the indicated days. Sclerotic glomeruli were not evident before
day 28. *P<0.05 compared to the untreated uninephrectomized controls (Day 0).
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Figure 3.8. Histological changes occurring in the vessels examined at the following time points: Aday 8, B-day 15, C-day 22, D-day29, E-day 42, and F-day 42. All pictures were taken at 600x. Part F
demonstrates the plexiform structures present.
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CHAPTER IV

A Moderately High Fat, Salt-Supplemented Diet May Promote Hypertension in
Obese Zucker Rats by Inhibiting Renal Nitric Oxide Synthase Activity
A Manuscript to be Submitted for Publication
Ryan G. Morrison, Caroline N. Mills, Antoinette L. Moran, Chelsea E. Walton,
Mohamed H. Sadek, Elsa I. Mangiarua, Paulette S. Wehner, and William D. McCumbee
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Abstract
Objective(s): The objective of the present study was to evaluate the obese Zucker rat as
model of obesity-hypertension. A high fat, salt supplemented diet was used to determine
whether the obese Zucker rat was more susceptible to the development of hypertension.

Design: Eight-week-old female lean and obese Zucker rats were fed a diet high in fat
content or standard rat chow (control diet) for 10 weeks. From the 4th week until the 10th
week, 1% NaCl was added to their drinking water. Animals were sacrificed at the end of
the 10th week for analysis of blood leptin and insulin levels.

Methods: Blood pressure was measured at weekly intervals. Urinary excretion of nitric
oxide (NO) metabolites was determined by colorimetric assay at week 4 and 10. At the
end of the experiment, plasma insulin and leptin concentrations were determined by
radioimmunoassay and renal nitric oxide synthase (NOS) activity was assessed in kidney
homogenates.

Results: The blood pressure of obese, but not lean, Zucker rats on a high fat diet was
increased by 2 weeks after onset of salt supplementation. The excretion of NO
metabolites, a measure of systemic NO production, was inhibited by the high fat diet,
especially in obese rats. The high fat diet suppressed renal NOS activity in obese Zucker
rats on the high fat diet. The high fat diet increased plasma leptin in lean, but not obese,
Zucker rats. Conversely, the diet increased plasma insulin in obese, but not lean zucker
rats.
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Conclusions: Data from these experiments indicate that obese Zucker rats are more
sensitive than age- and gender-matched lean counterparts to the development of dietinduced hypertension in response to a moderately high fat, salt-supplemented diet.
Furthermore, this obesity-associated susceptibility to hypertension is linked to
deficiencies in NO production and availability caused, in part, by dietary NO synthase
inhibition.
Keywords: hypertension, nitric oxide, obese Zucker rat, diet-induced, high fat
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Introduction
The prevalence of obesity has recently skyrocketed in the United States and other
industrialized countries. According to the National Health and Nutrition Examination
Studies (NHANES), the prevalence of obesity, defined as a body mass index equal to or
greater than 30 kg/m2, more than doubled among adults in the United States from 1980 to
2000 (Flegal et al., 2002). The rise in the prevalence of obesity is a chief factor in the
increasing incidence of hypertension (Care, 2005) and other obesity-related disorders
such as coronary heart disease (Pi-Sunyer, 2002). According to risk estimates from the
Framingham Heart Study, obesity is linked to about 75% of male and about 65% of
female cases of hypertension (Davy and Hall, 2004; Garrison et al., 1987). Thus,
obesity-hypertension appears to be the most common form of essential hypertension.

Meaningful advances in the field of obesity-hypertension depend upon the development
of an assortment of animal models that have characteristics in common with those
observed in obesity-hypertension in humans. Thus far, several very good models of
obesity-hypertension have been developed using rats (Ernsberger et al., 1999b), dogs
(Rocchini et al., 1987), and rabbits (Carroll et al., 1996). Still, the field may benefit from
additional animal models because of the complex polygenic nature of obesityhypertension. This view is further reinforced by the observation that factors commonly
clustering with obesity (e.g. insulin resistance) that may play a role in promoting
hypertension are not uniformly present in obese hypertensives. At this juncture, it
appears that the most practical approach to the study of obesity-hypertension would be to
use a wide range of species/models.
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The obese Zucker rat (OZR), which is used extensively as a model of metabolic
syndrome X (Takaya et al., 1996), is also considered by some to be a viable model for
obesity-associated hypertension (Kurtz et al., 1989). Controversy exists, however, as to
whether the OZR is actually hypertensive. Some investigators have reported that the
OZR is not hypertensive relative to age- and gender- matched lean Zucker rats (Bunag
and Barringer, 1988; Morgan et al., 1995; Pamidimukkala and Jandhyala, 1996; Pawloski
et al., 1992; Reddy and Kotchen, 1992), whereas others have indicated that the OZR is
hypertensive (Alonso-Galicia et al., 1996; Ambrozy et al., 1991; Carlson et al., 2000;
Kurtz et al., 1989; Maher et al., 1995; Turner et al., 1995). In those studies where
hypertension was present, it was generally mild. The argument that the obese Zucker rat
is at a greater risk of developing hypertension has been bolstered by experiments from
our laboratory showing that obese rats are far more sensitive to deoxycorticosterone-saltinduced hypertension than lean rats of the same age and gender (Morrison et al., 2002).

Models of obesity that are based on dietary manipulations, such as increased fat
consumption, have been suggested to be particularly applicable to understanding human
obesity (Lauterio et al., 1994). In addition to promoting obesity, high dietary fat
consumption per se may be independently associated with hypertension. For example, in
the Dietary Approaches to Stop Hypertension (DASH) clinical trials, patients’ blood
pressures were lowered in the absence of weight loss by reducing the dietary content of
saturated fat (Delichatsios and Welty, 2005). Furthermore, high fat diets promote insulin
resistance, a condition implicated in the pathogenesis of hypertension, independently of
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obesity in animal models (Vessby, 2003; Woods et al., 2004). Still, it is not clear
whether high fat diets interact with obesity to promote hypertension. In part, this lack of
understanding is due to a very close and confounding relationship between high fat diets
and weight gain.

Another dietary factor which has received considerable scrutiny regarding its role in
hypertension is sodium chloride. Increased dietary salt consumption induces
hypertension in salt-sensitive, but not salt-resistant individuals (Facchini et al., 1999).
Since salt-sensitivity occurs at a much higher rate in obese individuals, obesityhypertension is thought by some to be a salt-sensitive form of hypertension (Diaz, 2002;
Rocchini, 2000). There are many hypotheses that have been proposed to explain the link
between salt-sensitivity and hypertension. One hypothesis, based on studies using both
human subjects and laboratory animals, suggests that salt-sensitivity of blood pressure
can be explained, at least in part, by an inability of the salt-sensitive subject to sustain or
increase NO production in response to high salt intake (Bragulat and de la Sierra, 2002;
Cubeddu et al., 2000; Kopkan and Majid, 2005; Manning et al., 2001). NO plays an
important role in the long term regulation of blood pressure through its effects on the
kidney: it mediates the tubuloglomerular feedback response to luminal sodium, renal
blood flow, and pressure natriuresis (Bachmann and Mundel, 1994; Cowley et al., 2003;
Raij and Baylis, 1995).

The objective of the present study was to further evaluate the obese Zucker rat as a model
of obesity-hypertension by exposing it to dietary factors that may promote hypertension.
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Lean and obese Zucker rats were fed a high fat diet that was later supplemented with salt
in the drinking water, in order to investigate whether obese rats were more inclined to
develop hypertension on this diet than lean rats. Our experiments indicate that (1) obese
Zucker rats develop marked hypertension in response to a high fat, salt-supplemented
diet, whereas lean Zucker rats do not (2) NO production and availability may be reduced
by a high fat diet, and (3) the resulting NO deficiency may be due, in part, to decreased
NO synthase activity.

Methods
Animals. Seven-week-old female lean (Fa/?) and obese (fa/fa) Zucker rats were
purchased from Charles River Laboratories (Wilmington, MA, USA) and allowed to
acclimate to the Marshall University Animal Resources Facility for one week prior to the
start of an experiment. The rats were housed in plastic cages with corn chip bedding in a
room having a 12 h light/dark cycle and maintained at an ambient temperature of 23±2
°C. All procedures using animals were reviewed and approved by the Marshall
University Institutional Animal Care and Use Committee.

Experimental protocol. Systolic blood pressure (SBP) was measured once weekly using
tail cuff plethysmography. Recordings were taken with a programmed
electrosphygmomanometer coupled to a pneumatic pulse transducer and tail cuff (NarcoBiosystems, Houston, Texas, USA).
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Food consumption, water consumption, and 24-hour urine output were measured weekly
by placing rats in stainless steel metabolic cages. The rats were given 24 hours to adapt to
the cages before measurements were taken or urine was collected. To help ensure a
consistent environment, the metabolic cages were placed in the same room in which the
rats were normally housed. After the 24-hour urine collection, the urine was centrifuged
to remove any particulate matter. Aliquots of the supernatant were then stored at -20oC
until used for analysis.

After basal measurements were obtained (week 0), the rats were divided into four groups.
One group of lean rats and one group of obese rats were maintained on a standard
balanced rodent diet (Rodent Diet 5001) for the duration of the experiment and one group
of lean rats and one group of obese rats were fed a high fat diet (formula D12266B:
Research Diets, New Brunswick, New Jersey, USA) during the same 10 week interval.
The high fat diet (Table 4.1) was the purified ingredient-version of the condensed milk
diet that is used to separate lean from obesity-prone outbred rats (Lauterio et al., 1994).
After 4 weeks, 1% NaCl was added to the drinking water of all four groups until the end
of the experiment. At the end of the experiment, the rats were euthanized by
exsanguination via cardiac puncture after being deeply anesthetized with an
intraperitoneal injection of ketamine HCl:xylazine (45:5 mg/kg). Blood was drawn into
heparinized syringes and the plasma was recovered by centrifugation and stored at -20oC
until used for analysis. After the rats were exsanguinated, their kidneys were removed
and homogenized in ice-cold EDTA-free homogenization buffer (50 mM phosphate
buffer, pH 7.5, containing 250 mM sucrose, 10 µg/ml aprotinin, 1 µg/ml leupeptin, and
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87 µg/ml phenylmethylsulfonylfluoride) using Duall glass homogenizers. The
homogenate was then centrifuged to remove cellular debris and the resultant supernatant
was stored at -70oC until used for analysis.

Analytical techniques. Plasma insulin and leptin levels were determined using [125I] rat
insulin and leptin radioimmunoassay kits according to the manufacturer’s instructions
(Linco, St. Charles, MO, USA). Nitric oxide production was estimated by measuring the
concentration of NO3 + NO2 in the urine with a nitric oxide quantitation kit (Active
Motif, Carlsbad, CA, USA). Total nitric oxide synthase (NOS) activity in whole kidney
homogenates was determined in duplicate using an assay kit (Cayman Chemical, Ann
Arbor, MI, USA) that measures the conversion of L-[3H] arginine to [3H] citrulline.
Reaction conditions were verified using 1 mM NG-nitro-L-arginine as a negative control.
All samples were measured in duplicate.

Statistics. Data is expressed as means ± SE. Statistical differences among means were
determined by two-way analysis of variance (2WANOVA) followed by a Tukey test. In
the case of leptin, multiple t-tests were subsitituted for 2WANOVA because the obese
and lean data sets were too unbalanced for ANOVA comparison. Differences were
determined to be statistically significant at p≤0.05. Statistical analysis was performed
using SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA).
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Results
Consumption of a high fat diet induced a greater weight gain than a standard balanced
rodent diet in both lean and obese rats, with the weight gain in obese rats being
considerably larger than that of lean rats (Fig. 4.1A). Despite substantial weight gain,
obese rats consuming a high fat diet had a reduced cumulative energy intake (CEI)
relative to obese rats on the standard control diet (Fig. 4.1B). We also observed that the
high fat diet did not affect the cumulative energy intake of lean animals. In addition,
obese rats on either diet had a greater energy efficiency ratio than lean rats fed the same
diet (the energy efficiency ratio measures how efficiently energy is converted to body
weight). This difference in energy efficiency ratios between lean and obese rats was
particularly noticeable when comparing rats on the high fat diet (Fig 4.1C).

Regardless of diet, plasma leptin and insulin levels were markedly elevated in obese rats
relative to lean rats by the time blood samples were obtained at the end of the study (Fig.
4.2). The high fat diet, however, had no effect on leptin levels in obese rats which is in
contrast to the significant rise in plasma leptin levels observed in lean rats on the high fat
diet (Fig. 4.2A). Conversely, plasma insulin levels were unaffected by the high fat diet in
lean rats, whereas they were significantly elevated in obese animals on the same diet (Fig.
4.2B).

A principal objective of this study was to determine whether obesity increases the risk of
developing salt-sensitive-hypertension in animals consuming a high fat diet. Both lean
and obese rats were fed either a high fat diet or a diet of standard rat chow for the
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duration of the study. Four weeks into the study, 1% NaCl was added to the drinking
water of all animals. Within 2 weeks of adding NaCl to the drinking water, the obese rats
on the high fat diet developed moderate hypertension (Fig. 4.3A). The peak systolic
blood pressure for obese rats on the high fat, salt-supplemented diet was 158 mm Hg.
From the 6th week until the end of the study, the blood pressures of obese rats on the high
fat, salt-supplemented diet were significantly higher than those of obese rats on the saltsupplemented control diet (Fig. 4.3A). By contrast, the blood pressures of lean rats were
hardly affected by dietary manipulation. Average blood pressures of lean rats on a high
fat, salt-supplemented diet never rose above 136 mm Hg, and only at one point was the
elevation in blood pressure statistically significant (Fig. 4.3B).

To test the hypothesis that a diminished capacity to produce nitric oxide (NO) is involved
in the development of hypertension in obese rats on the high fat, salt-supplemented diet,
urinary excretion of stable NO metabolites (NO2 and NO3) was measured in all the
treatment groups before and after salt supplementation. As shown in Figure 4.4, obese
Zucker rats on the control diet excreted significantly more stable NO metabolites (NOx)
than their lean counterparts on the same diet. Also, there was an increase in NOx
excretion in both lean and obese rats when the control diet was supplemented with NaCl
(Figure 4.4). This increase in NOx excretion was particularly striking in obese rats on the
control diet.

Results of this study also show that the high fat diet suppresses NOx excretion (Figure
4.5A). Again, the effect in obese rats is quite dramatic because of the pronounced rise in

93

urinary NOx excretion associated with an increased NaCl load. To test the hypothesis
that the decrease in NOx excretion by rats on the high fat diet is due, at least in part, to a
decrease in NO production, renal NO synthase activity was measured in whole kidney
homogenates obtained from week 10 animals. There was a significant suppression of NO
synthase activity in renal homogenates from obese rats on the high fat, salt-supplemented
diet relative to the obese control group (Fig. 4.5B). Renal NO synthase activity levels in
lean control, lean high fat, and obese control animals were similar.

Discussion
The objective of the present study was to evaluate the obese Zucker rat as a model of
obesity-associated hypertension using a high fat, salt-supplemented diet to induce
hypertension. Obese rats that were fed the high fat diet developed hypertension when
subjected to a salt load whereas lean rats did not. Moreover, blood pressures did not go
up in response to a salt load in either the lean or obese rats that were fed a diet of standard
rat chow. These results suggest that obesity increases the risk of developing hypertension
when the obese subject is exposed to a hypertensive challenge. This observation is
consistent with previous work in which we demonstrated that the obese Zucker rat was
more sensitive to DOCA-salt-induced hypertension than age- and gender-matched lean
rats (Morrison et al., 2002).

Blood pressures in the obese rats that were fed the high fat, salt supplemented diet
reached a plateau within a few weeks of being subjected to a salt load with the peak
blood pressure reaching 158 ± 4 mmHg. There was no overt evidence of renal damage at
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the end of the study and the practically all animals survived. Thus, this model of obesityhypertension could prove to be a useful model for studying long-term effects of moderate
hypertension. This model may also be particularly useful for studying the interaction of
obesity and hypertension on renal function since both hypertension (Morrison et al.,
2005; Morrison et al., 2002) and obesity (Kasiske et al., 1985; Magil, 1995; Shimamura,
1983) affect renal function in the Zucker rat.

The moderate hypertension induced by a high fat, salt-supplemented diet stands in sharp
contrast to the severity of the response of the obese Zucker rat to DOCA-salt-induced
hypertension. In the DOCA-salt model, a significant elevation in blood pressure was
evident within 4 days of the onset of treatment. The blood pressure peaked at levels in
excess of 195 mmHg. The mortality rate was high and histological analysis revealed an
end-stage kidney (Morrison et al., 2005). Because of the high mortality rate, the DOCAsalt model is only useful for short-term studies.

There is substantial evidence that the sensitivity of blood pressure to sodium intake may
be modulated by a variety of nutritional factors (Kotchen and Kotchen, 1997). In
particular, high fat diets have been shown to promote sodium and water retention
(Strazzullo et al., 2001). In the present study, the obese Zucker rat appears to exhibit
diet-induced salt-sensitivity of blood pressure in response to a high fat diet. The blood
pressure did not rise appreciably in obese rats on the high fat diet during the 4 week
interval prior to being subjected to a salt load. This is consistent with the observations of
Alavi et al. (1995) and Maher et al. (1995). When subjected to a salt load, blood pressure

95

rose in the obese Zucker rat on a high fat diet, but hardly changed in obese rats on a diet
of standard rat chow.

One mechanism through which high fat diets may promote salt-sensitivity involves the
disruption of renal NO function. NO plays an important role in the long term regulation
of blood volume and pressure through its effects on the kidney. NO mediates the
tubuloglomerular feedback response to luminal sodium, renal blood flow, and pressure
natriuresis (Bachmann and Mundel, 1994; Cowley et al., 2003; Raij and Baylis, 1995).
Furthermore, NO has well known vasodilatory properties in the vasculature (Cockcroft,
2005). Studies in laboratory animals and humans have suggested that salt-sensitivity of
blood pressure can be at least partly explained by an inability to sustain or increase NO
production in response to high salt intake (Cubeddu et al., 2000; Kopkan and Majid,
2005; Manning et al., 2001). Thus, increased production of NO appears to be a vital
physiological response for homeostatic management of blood pressure and volume under
conditions of increased salt consumption. Accordingly, NO metabolite excretion was
markedly increased after salt supplementation, reflecting increased systemic nitric oxide
production in response to sodium loading. Interestingly, obese Zucker rats on the control
diet exhibited higher systemic NO production than lean counterparts both before and after
salt supplementation, suggesting that this mechanism may be playing a greater regulatory
role in the obese rat than in the lean rat. Ingestion of the high fat diet markedly reduced
this effect, suggesting that it has a negative impact on systemic NO production. This
potential inhibitory effect of a high fat diet on NO production is also evidenced to a lesser
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extent in the lean Zucker rats, where NOx excretion was reduced slightly, but
significantly.

The phenotypic differences in physiologic responses to salt loading were further
investigated by directly measuring NO production in the kidney, where NO may play a
critical role in the chronic regulation of sodium retention and blood pressure (Cowley et
al., 2003). Renal NOS activity was reduced by the high fat diet in obese rats, but lean
rats were unaffected by the dietary modification, further demonstrating the increased
susceptibility of obese rats to diet-induced dysregulation of nitric oxide production.
These data suggest the effects of the high fat diet on nitric oxide production may promote
salt-sensitivity of blood pressure in obese Zucker rats.

The high fat diet significantly reduced urinary NO metabolite excretion in lean animals
by the end of the study, but it had no effect on renal NO production at this point. This
underscores the complexity of NO metabolism and the importance of other mechanisms
that ultimately may play a role in determining NO availability, such as the inactivation of
NO by oxidative stress. Recent studies have indicated that oxidative stress may rapidly
inactivate NO, reducing functional NO availability (Dobrian et al., 2003; Roberts et al.,
2003).

The underlying cause of obesity in obese Zucker rats is a missense point mutation in the
leptin receptor (Chua et al., 1996) that leads to severe leptin resistance and
hyperleptinemia. In our study, the high fat diet did not further exaggerate this

97

genetically-produced hyperleptinemia in OZRs, despite significant diet-induced weight
gain, suggesting that plasma leptin may have already achieved peak levels in response to
the aforementioned receptor defect. On the other hand, leptin levels were increased
more than five-fold after high fat feeding in lean Zucker rats, which have a normally
functioning leptin receptor. These phenotypic differences in leptin physiology may be
responsible, in part, for the divergence of blood pressure responses between lean and
obese rats on the experimental diet. Villarreal et al. (1998) have demonstrated a
significant natriuretic effect of exogenous leptin that is attenuated in obese Zucker rats,
suggesting that the genetically determined inability to respond to leptin in the obese
Zucker rat may lead to impaired natriuretic capacity. This impairment may promote saltsensitivity of blood pressure in obese Zucker rats. In contrast, lean rats with their
functioning leptin receptor may be able to maintain salt resistance. In addition to this
potential role in maintaining resistance to salt, a role for leptin-induced release of NO in
maintaining normal blood pressure homeostasis has also been suggested (Fruhbeck,
1999).

In conclusion, our data indicates that high dietary fat intake dramatically compounds saltsensitivity of blood pressure in genetically obese Zucker rats. This sensitivity is closely
correlated to derangements in the compensatory production of NO, which is inhibited by
high fat feeding in obese Zucker rats. In addition, leptin is implicated as a potential
mediator in the dysregulation of blood pressure in obese Zucker rats on a moderately high
fat, salt-supplemented diet. Taken together, the data suggests that multiple factors are
probably responsible for the salt-sensitivity of blood pressure in Zucker rats.
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Figures and Tables

Table 4.1. Energy composition of the control
and high fat diets. Macronutrient components
are given in kcal percentage.
Diet

Control

High Fat

Protein
Carbohydrate
Fat

23
65
12

17
52
32

Total kcal/g

4.00

4.41

100

Weight Gain, g/10 weeks

200

*+

A

150

+

100

*

50

0
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B
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OBHF

+

*+
CEI, MJ
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EER, g/J

5
4

*

+

LHF

OC

3
2
1
0
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Figure 4.1. Weight gain (A), cumulative energy intake (B) and energy efficiency ratio (C) for lean
and obese Zucker rats that were fed a high fat diet or standard balanced rodent (control) diet ad
libitum. LC = lean rats, control diet; LHF = lean rats high fat diet; OC = obese rats, control diet;
and OHF = obese rats, high fat diet. The cumulative energy intake (CEI) and energy efficiency ratio
(EER) were calculated as described in the methods. The number of rats per group: LC =17, LHF =
17, OC = 16 and OHF = 14. *p<0.05 for a diet comparison within a given phenotype; +p<0.05 for a
phenotype comparison within a given dietary treatment.
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Figure 4.2. Plasma leptin (A) and insulin (B) concentrations in lean control (LC), lean high fat
(LHF), obese control (OC) and obese high fat (OHF) groups after 10 weeks of dietary treatment. The
number of rats per group: 7 for LHF and n=8 for all other groups. *p<0.05 for a diet comparison
within a given phenotype; +p<0.05 for a phenotype comparison within a given dietary treatment.
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Blood Pressure, mm Hg
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Figure 4.3. Blood pressures of obese (A) and lean (B) Zucker rats on either a high fat or control diet.
All rats were being fed a control diet when blood pressures were obtained at week zero. Immediately
after week zero measurements were recorded, half of the lean and obese rats were placed on a high
fat diet (indicated by first arrow). After blood pressure measurements were recorded at week 4, the
drinking water of all groups was supplemented by 1% saline (indicated by second arrow). The
number of rats per group: 16 for obese groups and 18 for lean groups. *p<0.05 for comparison of
dietary treatment within the same phenotype at the same week.
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Urinary NOx Excretion, µmol/day
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Figure 4.4. NOx (NO2 plus NO3) excretion by lean control (LC) and obese control (OC) groups on
weeks 4 and 10. The number of rats per group: 9 for lean groups and 8 for obese groups. *p<0.001
for diet comparisons within a given phenotype at the same week; +p<0.05 for a phenotype
comparison within a given dietary treatment at the same week.
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Figure 4.5. NOx excretion and renal nitric oxide synthase (NOS) activity in lean control (LC), lean
high fat (LHF), obese control (OC), and obese high fat (OHF) groups after 10 weeks of treatment.
Number of rats per group: 7 for LHF and n=8 for all other groups. *p<0.05 for a diet comparison
within a given phenotype; +p<0.05 for a phenotype comparison within a given dietary treatment.
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CHAPTER V
Conclusions and Future Directions

Conclusions
We have characterized two models of obesity-hypertension using the obese Zucker rat.
Both models have the potential to yield new insights into the nature of obesityhypertension and may be useful in developing a better understanding of this complex
disease. In one model, hypertension was induced by the administration of
deoxycorticosterone acetate (DOCA) and salt excess. DOCA induces salt retention and a
volume-expansion-dependent form of hypertension. The hypertensive response was
clearly exacerbated in obese rats relative to age- and gender-matched lean controls that
were subjected to the same treatment regimen. The DOCA-salt treated obese Zucker rat
(DST-OZR) rapidly advanced to a state of severe hypertension and exhibited signs of end
stage kidney disease by the end of the study (Morrison et al., 2005). By six weeks, the
mortality rate in DST-OZRs climbed dramatically, making this model unsuitable for
longer-term investigations. The second model of obesity-hypertension involved feeding
rats a high fat diet and then subjecting them to a salt load. In this model, a more
moderate form of hypertension with a lower mortality rate (Morrison et al., 2002) and
less noticeable renal damage (personal communication, Dr. Betts Carpenter) developed in
the obese Zucker rat. In contrast, the response of lean rats to this treatment was marginal
and statistically insignificant. While few DST-OZRs survived more than 6 weeks beyond
the onset of treatment, HF-OZRs had barely developed hypertension by that point;
moreover, practically all HF-OZRs survived the 10-week long experimental treatment
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(n=32, data not shown). An impaired ability to respond to a salt load appears to be a
common characteristic of both of these models of obesity-hypertension. This may be a
useful feature of these models since dietary salt consumption has been linked to human
hypertension in general (MacGregor, 1983; MacGregor et al., 1989) and obesityassociated hypertension (Hsueh and Buchanan, 1994) in particular.

One aim of this research was to investigate a probable mechanism that could promote the
development of hypertension in the HF-OZR model. In this regard, our work indicates
that a dysfunction in the nitric oxide pathway may play a role in the pathophysiology of
obesity-hypertension in the HF-OZR. Results presented as part of this dissertation
clearly indicate that NO production is markedly suppressed by the high fat diet and that
this effect is due, in part, to the inhibition of NO synthase activity. In light of the
dramatic increase in NO production by obese rats that remain normotensive when
subjected to a salt load while on a standard control diet, the inhibition of NO synthase by
a high fat diet may indeed be a critical component of the mechanism underlying the
development of hypertension in this model.

Future Directions
Future investigations will attempt to further elucidate the roles of genetic and
environmental factors in the HF-OZR. Gene microarray analysis of cortical kidney
homogenates from HF-OZR rats has already been performed, providing semiquantitative
comparisons of the expression levels of over 9000 genes. Eventually, this data will be
probed using a sophisticated technique known as gene set enrichment analysis (GSEA),
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which allows the detection of cumulative changes in gene expression throughout multiple
a priori defined biological pathways (Curtis et al., 2005). This analysis could provide a
more comprehensive view of the mechanisms that may promote hypertension in response
to a high fat diet and genetic obesity. Moreover, experiments can be designed to
investigate whether the pathways that are implicated by the GSEA analysis may be
involved in the pathogenesis of obesity-hypertension.
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APPENDIX B
Cortical Kidney Microarray in HF-OZR
Methods: At the end of the high fat dietary study, whole kidneys were excised and flashfrozen in liquid nitrogen. Frozen kidneys were stored at -70 ºC until thawed on
RNAlater®-ICE according to the manufacturer’s instructions (Ambion, USA). Cortical
kidneys were excised and total RNA was extracted using RNEasy MIDI kit (Qiagen,
USA). RNA integrity was assessed using the Agilent Bioanalyzer® (Agilent
Technologies, Palo Alto, CA). 40 µg total RNA for 4 biological repeats per experimental
group were used in a balanced block experimental design with a MWG rat 10K array
(MWG, UK). Superscript Direct cDNA Labeling for Microarray (Invitrogen, USA) was
used for labeling. mRNA samples were fluorescently labeled by incorporating Cy3dCTP or Cy5-dCTP (Perkin-Elmer, USA) during reverse transcription. Hybridization
was done on Hybe Station (Genomic Solutions, USA). Microarrays were scanned using
ScanArray Express and quantified with ScanArray Express Software (Perkin-Elmer,
USA), and then analyzed with Genespring Software (Agilent, USA).
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Obese High Fat vs. Obese Control Diet
GENE ID

FOLD
INCREASE

DESCRIPTION

D26111_1

2.06

chloride channel putative; clc-k2s; clc-k2l

RATTUS01236

2.16

expression: liver kidney heart brain strains: shrsp wistar_kyoto
trembl||q9jmf4 ; complete cds; clone:2-31

RATTUS01691

2.50

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak018016|ak018016_1 riken full-length
enriched library; clone:5830455m19 - mus musculus

RATTUS01645

2.51

expression: kidney strains: shrsp wistar_kyoto trembl||q9qxp0 rh
type c glycoprotein

NM_033349_1

2.71

expression: liver kidney strains: sprague_dawley wistar_kyoto
gbp|u97667|u97667_1 rsp29 - rattus norvegicus; hydroxyacyl
glutathione hydrolase hagh

NM_030833_1

2.73

interferon-inducible protein 16 loc80875

RATTUS00354

3.06

expression: liver brain heart kidney strains: shrsp
sprague_dawley wistar_kyoto trembl||q9nwu5 cdna flj20594 fis;
clone kat08731

X62660_1

3.17

glutathione transferase

NM_052802_1

3.34

kidney androgen-regulated protein kap

RATTUS01543

3.60

expression: liver heart strains: sprague_dawley wistar_kyoto
gbp|ak012051|ak012051_1 riken full-length enriched library;
clone:2610319b19 - mus musculus

RATTUS02152

3.78

expression: brain kidney strains: shrsp
gbp|ak027689|ak027689_1 cdna flj14783 fis; clone
nt2rp4000541 unnamed protein product - homo sapiens

RATTUS00919

4.73

expression: liver brain strains: shrsp sprague_dawley
wistar_kyoto trembl||o88783 coagulation factor v

RATTUS01707

4.76

expression: kidney strains: wistar_kyoto
gbp|ak003647|ak003647_1 riken full-length enriched library;
clone:1110012o14 - mus musculus

GENE ID

FOLD
DECREASE

DESCRIPTION

NM_020976_1

2.05

kidney-specific membrane protein nx-17

U00926_1

2.08

delta subunit of f1f0 atpase
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M36410_1

2.13

sepiapterin reductase ec 1.1.1.153

NM_017081_1

2.16

hydroxysteroid dehydrogenase; 11 beta type 2 hsd11b2; 11beta-hydroxylsteroid dehydrogenase

AF029886_1

2.17

microphthalmia associated transcription factor microphthalmia

NM_017314_1

2.25

polyubiquitin ubc; ubiquitin c

NM_017314_1

2.29

polyubiquitin ubc; ubiquitin c

NM_022399_1

2.34

d-beta-hydroxybutyrate dehydogenase; calreticulin; calr;
precursor aa -17 to 399

NM_031090_1

2.44

ras-related protein rab1; ras

NM_053576_1

2.44

acidic calcium-independent phospholipase a2 aipla2; thiolspecific antioxidant protein prdx5; tsa

M96377_1

2.58

neurexin ii-beta-a

S61973_1

2.64

nmda receptor glutamate-binding subunit

RATTUS01564

2.64

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak009057|ak009057_1 riken full-length
enriched library; clone:2310001a20 - mus musculus

RATTUS01409

2.67

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|af195142|af195142_1 selenoprotein r - mus
musculus

NM_017245_1

2.76

eukaryotic translation elongation factor 2 eef2; ef-2; aa 1-858

RATTUS02428

2.87

expression: brain strains: shrsp sprague_dawley wistar_kyoto
mwg own new gene sequence

NM_031012_1

3.02

kidney zn-peptidase precursor; aminopeptidase m apm; anpep

NM_017147_1

3.21

cofilin 1; non-muscle cfl1

NM_031354_1

3.24

mitochondrial voltage dependent anion channel vdac2; voltagedependent 2

S78284_1

3.27

bcl-x short form; bcl-xshort; bcl-x-long; bcl-xalpha

NM_012783_1

3.31

basigin ox47 antigen or ce-9 emmprin in human neurothelin; ht7
or 5a11 in avian bsg; mrc; transmembrane glycoprotein

RATTUS00028

3.40

expression: heart brain strains: shrsp sprague_dawley
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family
protein nd1-l - mus musculus

NM_053840_1

3.56

put. ggt light subunit 380-568 protein sequence is in conflict with
the conceptual translation; gamma-glutamyl transpeptidase ec
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2.3.2.2; m33821; precursor aa 4-568; gammaglutamyltranspeptidase 1-568
NM_013013_1

3.68

prosaposin sulfated glycoprotein; sphingolipid hydrolase
activator psap; glycoprotein precursor; glycoprotein-1
glycoprotein-1; sgp-1; prosapo>; prosaposin; sgp-1

NM_023950_1

4.19

rab7; member ras oncogene family rab7; gtp-binding protein;
ras-related p23

NM_017173_1

4.26

serine proteinase inhibitor; clade h heat shock protein 47;
member 1 serpinh1; collagen-binding gp46

NM_020076_1

4.28

3-hydroxyanthranilate 3;4-dioxygenase haao

NM_031605_1

4.44

cytochrome p450; 4a10 cyp4a10; p450

NM_022866_1

4.68

sodium-dependent high-affinity dicarboxylate transporter 3
nadc3; sdct2

NM_024149_1

4.96

adp-ribosylation factor 5 arf5

S69315_1

6.51

endoplasmin grp94

RATTUS00063

11.31

expression: liver brain heart kidney strains: shrsp
sprague_dawley wistar_kyoto gbp|x02344|x02344_1 beta 2
beta-tubulin - homo sapiens; trembl||q9jjy6 fragment
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GENE ID

FOLD
INCREASE

DESCRIPTION

D16478_1

2.05

mitochondrial long-chain enoyl-coa hydratase/3-hydroxycyl-coa
dehydrogenase alpha-subunit rtp-alpha

NM_052802_1

4.16

kidney androgen-regulated protein kap

GENE ID

FOLD
DECREASE

DESCRIPTION

AJ238391_1

2.06

sulfotransferase k1 sultk1; k2 sultk2

NM_053864_1

2.10

transitional endoplasmic reticulum atpase; valosin-containing
protein vcp

RATTUS03589

2.12

expression: brain strains: shrsp sprague_dawley trembl||q9nsn1
hypothetical 110.4 kda protein fragment

RATTUS00172

2.14

expression: kidney heart brain strains: shrsp sprague_dawley
wistar_kyoto gbp|m74773|m74773_1 spnb-2 brain beta spectrin
- mus musculus

NM_012504_1

2.20

atpase; na+k+ transporting; alpha 1 polypeptide atp1a1; na+;k+atpase alpha-subunit precursor; na+ and k+ catalytic subunit;
na;k-atpase alpha-1; atpase aa -4 to -1

NM_053837_1

2.21

rat assembly protein ap50 associated with clathrin-coated
vesicles; adaptor-related complex 2; mu 1 subunit ap2m1

NM_053576_1

2.28

acidic calcium-independent phospholipase a2 aipla2; thiolspecific antioxidant protein prdx5; tsa

RATTUS02848

2.31

expression: kidney heart strains: shrsp sprague_dawley
wistar_kyoto gbp|ak010581|ak010581_1 riken full-length
enriched library; clone:2410024g15 - mus musculus;
gbp|u51014|u51014_1 pep4 prolidase

NM_017233_1

2.32

4-hydroxyphenylpyruvic acid dioxygenase hpd; 4hydroxyphenylpyruvate hppd; f alloantigen

NM_053752_1

2.41

succinate-coa ligase; gdp-forming; alpha subunit suclg1;
succinyl-coa synthetase ec 6.2.1.4

NM_022399_1

2.60

d-beta-hydroxybutyrate dehydogenase; calreticulin; calr;
precursor aa -17 to 399

AF029886_1

2.78

microphthalmia associated transcription factor microphthalmia
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NM_019134_1

2.86

solute carrier family 12; member 1 bumetanide-sensitive sodium[potassium]-chloride cotransporter slc12a1; sodium- potassium –
chloride

U30290_1

3.05

galanin receptor galr1

NM_012615_1

3.09

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_021594_1

3.32

erm-binding phosphoprotein loc59114

S61973_1

3.33

nmda receptor glutamate-binding subunit

NM_013085_1

3.46

urinary plasminogen activator; urokinase plau; urikinase-type
activator; upa

NM_021266_1

3.55

drosophila polarity gene frizzled homologue fzd1

RATTUS00794

3.66

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak007469|ak007469_1 riken full-length
enriched library; clone:1810013b01 - mus musculus

RATTUS00028

3.67

expression: heart brain strains: shrsp sprague_dawley
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family
protein nd1-l - mus musculus

NM_021740_1

3.86

alpha-prothymosin myc-regulated gene; prothymosin precursor;
prothymosin-alpha; alpha ptma

RATTUS03021

4.56

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|bc003903|bc003903_1 glutathione stransferase theta 1 - mus musculus

M24359_2

5.33

m2 pyruvate kinase pk

NM_012886_1

5.70

tissue inhibitor of metalloproteinase 3 timp-3; timp3

Z11994_1

6.36

45kda protein

NM_013214_1

6.72

cytosolic peroxisome proliferator-induced acyl-coa thioesterase;
hydrolase rbach; rlach1; acyl coenzyme a thioester
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GENE ID

FOLD
INCREASE

DESCRIPTION

NM_012939_1

2.12

cathepsin h pre-pro-peptide; rch11; ctsh

AJ309926_1

2.19

ion channel asic 1b; asic-beta

NM_020976_1

2.24

kidney-specific membrane protein nx-17

S76779_1

2.25

apolipoprotein e rapoe; apoe

NM_031012_1

2.30

kidney zn-peptidase precursor; aminopeptidase m apm; anpep

M35052_1

2.55

f-0-atpase subunit b precursor

RATTUS00729

2.56

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak004817|ak004817_1 riken full-length
enriched library; clone:1200017c17 - mus musculus

RATTUS01564

2.63

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak009057|ak009057_1 riken full-length
enriched library; clone:2310001a20 - mus musculus

M36410_1

2.72

sepiapterin reductase ec 1.1.1.153

RATTUS01409

2.80

expression: liver brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|af195142|af195142_1 selenoprotein r - mus
musculus

NM_022266_1

2.80

connective tissue growth factor ctgf

RATTUS00443

2.90

expression: heart brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|aj310346|aj310346_1 paf67 67 kda
polymerase-associated factor paf67 - mus musculus

NM_031031_1

3.33

l-arginine: glycine amidinotransferase gatm; l-arginine:glycine

NM_021757_1

3.45

pleiotropic regulator 1 plrg1

RATTUS00249

3.51

expression: liver heart kidney brain strains: shrsp
sprague_dawley wistar_kyoto trembl||caa02861 sequence 56
from patent wo9520654

NM_022947_1

3.52

suppressor of k+ transport defect 3 skd3

NM_017306_1

4.40

dodecenoyl-coenzyme a delta isomerase 3;2 trans-enoylcoenyme a isomerase dci; delta-3;delta-2-enoyl-coa; 3-2transenoyl-coa

NM_053314_1

4.54

potassium inwardly-rectifying channel; subfamily j; member 16
kcnj16; kir5.1; inward rectifier potassuim channel 9
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NM_031605_1

5.63

cytochrome p450; 4a10 cyp4a10; p450

NM_013098_1

17.43

glucose-6-phosphatase catalytic subunit g6pase; g6pc

GENE ID

FOLD
DECREASE

DESCRIPTION

RATTUS00548

2.47

expression: heart brain kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak010275|ak010275_1 riken full-length
enriched library; clone:2400003o04 - mus musculus

NM_053319_1

2.65

protein inhibitor of neuronal nitric oxide synthase pin; dynein;
cytoplasmic; light peptide

X61296_2

2.66

orf2 consensus sequence encoding endonuclease and reverse
transcriptase minus rnaseh; unknown protein; orf 2; open
reading frame

RATTUS02304

2.87

expression: liver kidney strains: shrsp sprague_dawley
wistar_kyoto gbp|ak002802|ak002802_1 riken full-length
enriched library; clone:0610038k03 - mus musculus

U67995_1

4.54

stearyl-coa desaturase 2

NM_013214_1

17.53

cytosolic peroxisome proliferator-induced acyl-coa thioesterase;
hydrolase rbach; rlach1; acyl coenzyme a thioester
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Lean High Fat vs. Lean Control Diet
GENE ID

FOLD
INCREASE

DESCRIPTION

NM_012793_1

2.07

guanidinoacetate methyltransferase precursor; gamt

NM_031012_1

2.18

kidney zn-peptidase precursor; aminopeptidase m apm; anpep

M35052_1

2.29

f-0-atpase subunit b precursor

NM_021765_1

2.57

beta prime cop copb

NM_012771_1

2.64

lysozyme lyz

RATTUS03013

2.78

expression: kidney strains: wistar_kyoto trembl||q9jmg1 ;
complete cds; clone:1-9

RATTUS00582

2.80

expression: kidney heart strains: shrsp sprague_dawley
wistar_kyoto gbp|ak007386|ak007386_1 riken full-length
enriched library; clone:1810008o21 - mus musculus

NM_053021_1

3.50

testostrone-repressed prostate message 2 clu; clusterin; putative
open reading frame; sulfated glycoprotein precursor; trpm-2

NM_012992_1

4.57

nucleoplasmin-related protein nuclear protein b23 npm1;
nucleolar; b23.1

RATTUS01085

5.88

expression: liver brain heart strains: shrsp sprague_dawley
wistar_kyoto gbp|ak014338|ak014338_1 riken full-length
enriched library; clone:3230402m22 - mus musculus

NM_017306_1

7.16

dodecenoyl-coenzyme a delta isomerase 3;2 trans-enoylcoenyme a isomerase dci; delta-3;delta-2-enoyl-coa; 3-2transenoyl-coa

RATTUS01484

13.43

expression: liver strains: shrsp wistar_kyoto
gbp|m17440|m17440_1 c4a complement component c4a - mus
musculus

GENE ID

FOLD
DECREASE

DESCRIPTION

NM_012615_1

1.98

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_012615_1

2.05

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_012615_1

2.08

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_053792_1

2.08

selective lim binding factor; rat homolog slb; factor

NM_031535_1

2.09

b cell lymphoma 2 like bcl2l; bcl-xbeta
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NM_053598_1

2.10

diphosphoinositol polyphosphate phosphohydolase type ii nudt4

D30804_1

2.13

proteasome subunit rc6-1

NM_012615_1

2.16

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_013059_1

2.18

tissue-nonspecific alp alkaline phosphatase alpl; precursor
polypeptide aa -17 to 507

NM_031774_1

2.29

rab acceptor 1 prenylated rabac1; pra1

X67788_1

2.35

ezrin; p81

NM_012497_1

2.54

aldolase c; fructose-biphosphate aldoc; c

NM_032617_1

2.62

rab11b; member ras oncogene family rab11b; gtp-binding
protein; gtp binding rab11-p24-b

NM_012615_1

2.79

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

NM_031523_1

2.80

nerve growth factor; gamma polypeptide ngfg; kallikrein
precursor; ps; s3; kal; 1; renal/pancreas/salivary klk1

NM_017248_1

3.00

heterogeneous nuclear ribonucleoprotein a1 hnrpa1; helix
destabilizing protein

RATTUS03589

3.02

expression: brain strains: shrsp sprague_dawley trembl||q9nsn1
hypothetical 110.4 kda protein fragment

RATTUS01421

3.07

expression: heart brain kidney strains: shrsp wistar_kyoto
trembl||q9jj97 brain cdna; clone mncb-0091

AF273025_1

3.22

amino acid system n transporter

M24930_1

3.27

mhc a-beta rt1.b-b-beta cell surface glycoprotein; class ii antigen
b beta-chain rt1.bbeta; integral membrane protein rt1.b; a<beta>;
rt1.b-1

NM_031523_1

3.32

nerve growth factor; gamma polypeptide ngfg; kallikrein
precursor; ps; s3; kal; 1; renal/pancreas/salivary klk1

RATTUS00028

3.44

expression: heart brain strains: shrsp sprague_dawley
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family
protein nd1-l - mus musculus

NM_012615_1

3.49

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

S62903_1

3.60

genetic hypertension component sa

RATTUS01155

3.64

expression: brain strains: shrsp sprague_dawley wistar_kyoto
trembl||o08551 serine/arginine-rich protein specific kinase 2 ww
domain binding protein 6 fragment

NM_012615_1

3.65

ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1

133

NM_031763_1

3.98

platelet-activating factor acetylhydrolase beta subunit paf-ah
beta pafah1b1

NM_023102_1

5.35

casein kinase 1 gamma 2 isoform csnk1g2

U67995_1

7.17

stearyl-coa desaturase 2
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Curriculum Vitae

Ryan Morrison
Department of Pharmacology, Physiology, and Toxicology
Marshall University, Joan C. Edwards School of Medicine
1542 Spring Valley Drive
Huntington, WV 25704

EDUCATION
Marshall University:
□

Ph.D. in Biomedical Sciences (January 2000 - May 2006)

□

M.B.A. (January 2003 – August 2005)

□

B.S. Biology ( August 1995 – December 2000)

Graduate GPA: 3.62

Total Undergraduate/Graduate Hours: 182/204

PUBLICATIONS IN PEER-REVIEWED JOURNALS
□ Morrison RG, Carpenter AB, Adams VL, Mangiarua EI, Wehner PS, McCumbee WD.
Progression of renal damage in the obese Zucker rat in response to
deoxycorticosterone acetate-salt-induced hypertension. Ann Clin Lab Sci. 2005
Winter;35(1):54-65.
□ Wright GL, Morrison R, Fultz ME, Wright G, McCumbee W, Wehner P, Studeny M.
Effect of fasting on vascular contractility in lean and obese Zucker rats. Clin Nutr.
2003 Aug;22(4):359-63.
□ Morrison RG, Carpenter AB, Moore SK, Mangiarua EI, Valentovic MA, Walker EM Jr,
Wehner PS, Rhoten WB, Touchon RC, McCumbee WD. Increased sensitivity of the
obese Zucker rat to deoxycorticosterone-salt- induced hypertension. J Hypertens.
2002 Nov;20(11):2247-55.
o Selected for Editorial Commentary:
Kenyon CJ. Mineralocorticoid-induced hypertension in obese Zucker rats. J
Hypertens. 2002 Nov;20(11):2151-2. Review. No abstract available.
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PRESENTATIONS AT NATIONAL SCIENCE MEETINGS
□ Annual Meeting of the American Society of Hypertension
San Francisco, California, May 2001
“Increased Sensitivity of the Obese Zucker Rat to DOCA-Salt-Induced Hypertension”
R.G. Morrison, S.K. Moore, E.I. Mangiarua, G.L. Wright, and W.D. McCumbee
□ Annual Meeting of the Federation of American Societies for Experimental Biology
San Diego, California, May 2005
“Nitric Oxide and Diet-Induced Hypertension in the Obese Zucker Rat”
Ryan G. Morrison, Antoinette L. Moran, Chelsea E. Walton, Mohamed H. Sadek, Paulette
S. Wehner, Elsa I. Mangiarua, and William D. McCumbee

PRESENTATIONS AT LOCAL SCIENCE MEETINGS
□ Marshall University Research Day
Huntington, West Virginia, 2003
“Effects of Zocor on Blood Pressure and Kidney Function in Obese Rats With
Mineralocorticoid-Induced Hypertension”
R.G. Morrison, I. Arif, E. Dager, A.B. Carpenter, E.I. Mangiarua, W.D. McCumbee
□ MU Research Day, 2001
Huntington, West Virginia, 2001
“Increased Sensitivity of the Obese Zucker Rat to DOCA-Salt-Induced Hypertension”
R.G. Morrison, S.K. Moore, E.I. Mangiarua, G.L. Wright, and W.D. McCumbee
□ Listed as coauthor and helped present posters for 3 different BRIN student projects
at WV-BRIN meetings, 2003-2004
□ 2 Undergraduate Sigma Xi poster presentations, 1999

ADDITIONAL RESEARCH EXPERIENCE
□ Undergraduate Research in Chemistry, 1998
developed a procedure for detecting lead in water utilizing scanning electron microscopy
of electrodeposited samples on a microscale surface
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PRESENTATIONS AT REGIONAL BUSINESS MEETINGS
□ Proceedings of the Southeast Case Research Association Annual Meeting
Myrtle Beach, South Carolina, February 2006
“Jacob Supply Company”
with Uday Tate, Ashley Collins, Kim Congrove, and Blaker Bolling

INVITED LECTURES
□ Continuing Medical Education Lecture for Cardiology Group
Saint Mary’s Hospital, Huntington, WV, 2004
“Obesity and Renal Disease”
□ Continuing Medical Education Lecture for Cardiology Group
Saint Mary’s Hospital, Huntington, WV, 2005
“Molecular Mechanisms of Cardiac Hypertrophy”

PUBLISHED ILLUSTRATIONS
□ Designed and Produced Scientific Figures
Carpenter, AB. “Immunoassays for Diagnosis of Infectious Diseases” in Manual of
Clinical Microbiology. 9 th Ed. In Press 2006. Murray PR, Baron EJ, Pfaller MA,
Tenover FC, Yolken RH (Eds.)

AWARDS
□ WV PROMISE scholarship, August 1995
□ COS Undergraduate Research Scholarship, January 1999
□ Special Travel Award from Dean of Graduate Studies, May 2005
□ Special Travel Award from Provost, May 2005
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TECHNICAL PROFICIENCIES
□ Biomedical Science:
rodent handling (anesthesia and surgery), enzymatic/colorimetric assays, ELISAs,
RIAs, RNA extraction and analysis, protein extraction and analysis
□ Computer:
highly developed computer-literacy , skilled in all Microsoft Office products (65 wpm
and numpad proficient), Sigmastat/Sigmaplot Statistical Software, Adobe
Photoshop and Illustrator, Endnote Citation Management Software

MANAGEMENT EXPERIENCE
□ Managed research lab, 2003-2006
trained new graduate students, technicians, and BRIN undergraduate students,
organized and maintained inventory

CLASSROOM-BASED PRESENTATIONS
□ Japanese Healthcare System
□ The Electronic Medical Record
□ The Metabolic Syndrome
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